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CHAPTER 1 
INTRODUCTION 
Cognitive aging is a complex phenomenon that reflects multiple biological and 
behavioral changes. There is growing evidence that vascular risk is one of the important 
contributors to the development of age related cognitive declines. In recent years, one 
contributor to vascular risk, systemic inflammation (Hansson, 2005), has been 
increasingly examined as a source of cognitive decline and dementia. Cardiovascular 
disease (CVD) is the leading cause of death in the United States (Kung, Hoyert, Xu, & 
Murphy, 2007) and several modifiable risk factors (e.g., smoking, dyslipidemia, 
hypertension, diabetes, abdominal obesity, nutritional intake, alcohol consumption, and 
physical activity) for the development of CVD have been identified (Calabrò, Golia, & 
Yeh, 2009). Together, these modifiable risk factors contribute to nearly 90% of all cases 
of mortality (Danaei et al., 2009). Nonetheless, nearly half of all cases of CVD have no 
identifiable risk factor other than age and gender, a finding which has sparked interest in 
identifying additional markers (Calabrò et al., 2009). Within the past decade, a new 
group of risk factors for CVD has emerged, several of which have also been implicated 
as modifiers of cognitive aging, presumably through their inflammatory effects in the 
central nervous system (CNS). Elevations in plasma levels of C-reactive protein (CRP) 
and homocysteine (Hcy) are two such risk factors that have been assessed in this 
capacity. 
Role of CRP and Hcy in the Development of Atherosclerosis 
Following an injury or infection, risk factors for atherosclerosis (e.g., 
hypertension, smoking, hyperglycemia, and viruses) contribute to endothelial 
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dysfunction by altering the intimal layer, increasing its permeability, and allowing the 
adhesion of leukocytes and platelets to the endothelium. These in turn facilitate 
monocyte adhesion to the endothelial wall and their subsequent migration into the 
intima, which then become macrophages with the ingestion and oxidation of lipids and 
low-density lipoproteins (LDL). The macrophages in an attempt to correct the tissue 
damage, become foam cells and initiate the fatty streak, which contributes to the 
formation of an atheromatous lesion by releasing enzymes that break down the collagen 
and smooth muscle cells in the atherosclerotic cap, causing it to weaken, and thereby 
exposing the atherosclerotic core, rendering it susceptible to rupture and thrombosis 
(Katrinchak & Fritz, 2007; Patrick & Uzick, 2001; Pearson et al., 2003).   
A disturbance in immunological homeostasis such as that caused by injury or 
infection also leads to a parallel activation of cytokines (e.g., interleukin [IL]-6, IL-1, and 
tumor necrosis factor [TNF]-α), acute phase reactants (e.g., CRP, serum amyloid A), 
and other proteins (Patrick & Uzick, 2001; Pearson et al., 2003). A growing body of 
evidence supports CRP as a causal factor in every aspect of atherogenesis, from the 
initial recruitment of leukocytes to endothelial dysfunction (Calabrò et al., in 2009). The 
evidence includes in vivo experimentation in humans, where a single bolus infusion of 
CRP provoked an immediate and simultaneous decline in endothelial-dependent 
vasodilation and stimulation of CRP-mediated coagulation processes (Bisoendial et al., 
2007).  
Conversely, the link between atherosclerosis and Hcy is less clear. However, 
several plausible mechanisms for Hcy-induced atherosclerosis have been suggested 
including putative effects on monocytes, coagulation factors, and adhesion molecules; 
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reduced endothelial reactivity; increased proliferation of smooth muscle cells; promotion 
of lipoprotein oxidation and platelet activation (Miller, 2001; Seshardi, 2006; Spence, 
2007; Trabetti, 2008); and in human cells, there is evidence for increased cytokine 
expression and activation of monocytes and their proliferation, while inhibiting 
macrophage migration inhibitory factor (Su, Huang, Pai, Liu, & Chang, 2005). Moreover, 
studies have demonstrated a positive association between hyperhomocysteinemia and 
CRP, and CVD is accompanied by elevations in both CRP and Hcy (Holven et al., 2006; 
van den Kommer, Dik, Comijs, Jonker, & Deeg, in press; Youssef, Mojiminiyi, & Abdella, 
2007), suggesting there is also a point of interaction for CRP and Hcy in the 
development of atherosclerosis.  
Biochemistry and Synthesis of CRP and Hcy 
CRP is a pleiotropic plasma protein, having both pro-inflammatory (e.g., up-
regulation of adhesion molecule expression in endothelial cells, enhancement of 
phagocytosis, stimulation of cytokines) and anti-inflammatory (e.g., interactions with 
ligands, binding with immunoglobulin receptors) effects. In plasma, CRP is a pentameric 
structure, having five sub-units. With the loss of this structure however, a modified or 
monomeric CRP results which is naturally occurring in tissue, and also exerts 
atherogenic effects, although to a lesser degree than pentameric CRP. In all likelihood, 
the function of CRP is context-dependent and can either enhance or dampen 
inflammatory responses depending on the circumstance (Black, Kushner, & Samols, 
2004; Paffen & deMaat, 2006). 
CRP is primarily synthesized in the liver by hepatocytes and regulated by IL-6 
and to a lesser extent by IL-1 and TNF, although extrahepatic synthesis of CRP has 
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also been reported in neurons, atherosclerotic plaques, monocytes, and lymphocytes 
(Black et al., 2004; Katrinchak & Fritz, 2007). CRP is an acute phase reactant, and as 
such, plasma levels of CRP increase markedly, as much as 1000-fold, in response to 
tissue injury including that caused by infection, trauma, malignant disease, and chronic 
inflammatory conditions. Post-injury, CRP can be found in high levels in areas of tissue 
damage, such as the intimal layer of the atherosclerotic artery and in foam cells of 
atherosclerotic plaques (Black et al., 2004; Hackam & Shumak, 2004). Hcy, a non-
essential sulfur-containing amino acid linking the methionine and cysteine cycles, can 
be derived from the addition of a methylene group to the naturally occurring amino acid 
cysteine (transsulfuration), or the loss of a methyl group from thiol (remethylation) via S-
adenosyl methionine. The latter is a positive allosteric effector for the transsulfuration 
pathway, and a negative allosteric effector for the remethylation pathway (see Figure 1).  
The bulk of circulating Hcy is cellular in origin and is derived from the metabolism 
of methionine. However, a limited amount of Hcy is of a dietary origin, and varies 
according to protein content and vitamin sufficiency. With the consumption of a protein-
rich meal, methionine concentration is increased, and the transsulfuration pathway 
takes the dominant role, resulting in Hcy catabolism to cysteine. Conversely, when 
dietary methionine is low, the remethylation pathway is favored with the conversion of 
Hcy back to methionine. At least three B-complex vitamins are essential for Hcy 
homeostasis: B6 (pyridoxine), B9 (folate), and B12 (cobalamin), though to variable 
degrees in the two pathways. Methionine synthase, the enzyme involved in converting 
Hcy to methionine in the remethylation reaction requires both B9 and B12 as 
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cofactors. In the transsulfuration pathway, Hcy is converted to cysteine by the enzymes 
cystathionine-β-synthase and cystathionine-γ-lyase, which require B6 as a cofactor (see 
Figure 1). Therefore, B6, B9, and B12 deficiency causes hyperhomocysteinemia, with low 
folate being the strongest determinant of total plasma Hcy (tHcy; Jacobsen, 2000; 
Joubert & Manore, 2006). 
 
Figure 1 
Homocysteine Metabolism. Adapted from Chanson et al., 2007; Joubert & Manore, 
2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Role of Inflammation in Cognitive Decline 
Inflammation has been associated with cognitive decline with some consistency 
suggesting systemic inflammation may be involved in the pathophysiology of cognitive 
decline, and in particular Alzheimer’s Disease (AD). Several lines of evidence support 
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this hypothesis. First, areas of the brain affected by AD also show signs of astro- and 
microgliosis in response to activation of the inflammatory cascade, of which CRP is a 
part. Specifically, cellular byproducts of this complementary cascade are seen in higher 
concentrations in the serum of AD patients and co-localize at areas affected by AD 
pathology (i.e., neuritic plaques, neurofibrillary tangles). Second, inflammatory cytokines 
and β-amyloid (Aβ) reciprocally act on one another: proinflammatory cytokines augment 
amyloid precursor protein expression, which in turn, through β-amyloid, induces the 
release of inflammatory cytokines. Third, several inflammatory single nucleotide 
polymorphisms (SNPs) have been associated with reductions in AD risk. Last, non-
steroidal anti-inflammatory drugs have been shown to delay the onset or slow the 
progression of AD in several epidemiological studies (Casserly & Topol, 2004; Dziedzic, 
2006).  
 Similarly, Hcy has also been implicated in the pathophysiology of AD because in 
high concentrations, Hcy is neurotoxic and can cause neuronal degeneration and 
alterations in plasticity (Obeid & Hermman, 2006; Sachdev, 2005). Several mechanisms 
for hyperhomocysteinemia neurotoxocity have been proposed including increased 
oxidative stress through the generation of oxygen free radicals and the reduced activity 
or bioavailability of endogenous antioxidants; excitotoxicity through activation of 
glutamatergic N-methyl-D-aspartate (NMDA) receptors; promotion of apoptosis through 
impaired transmethylation leading to DNA breakage; and alterations to protein function 
resulting in inhibition of Na+/K+ ATP-ase activity. Hcy also interacts directly with amyloid 
and tau pathways to accelerate dementia. Specifically, it induces an Hcy-responsive 
endoplasmic reticulum stress protein, Herp, which interacts with presenilin 1 and 2 to 
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increase Aβ generation in culture, and Hcy sensitizes hippocampal neurons to the 
neurotoxic effects of insoluable Aβ. Hcy also promotes tau phosphorylation by inhibiting 
protein phosphatase 2 activity (Obeid & Hermann, 2006; Raman et al., 2007; Sachdev, 
2005; Seshardi, 2006).  
Alzheimer’s type pathology is only one cause of cognitive decline however, and a 
large body of evidence suggests CRP and Hcy have a causal role in the development of 
other forms of cognitive decline, such as vascular dementia (VaD). VaD frequently 
results from a cerebrovascular disease, which in itself may stem from an accumulation 
of cardiovascular risk factors. Endothelial damage seems to be the final common 
pathway of several vascular risk factors with the brain as the major target for end-organ 
damage because of its large small-vessel microcirculatory endothelial surface (Román, 
2005). Several cardiovascular and cerebrovascular diseases have been independently 
linked with elevations in CRP including myocardial infarction, peripheral arterial disease, 
sudden cardiac death, transient ischemic attack, and stroke, many of which are 
associated with the development of VaD (Black et al., 2004; Paffen & deMaat, 2006). 
Indeed, in a prospective population study of Japanese men, elevations in CRP at midlife 
predicted AD, VaD, and AD with contributing cerebrovascular disease in late life 
independent of other vascular risk factors (Schmidt et al., 2002). 
With regard to Hcy, diet-induced hyperhomocysteinemia in mice is associated 
with microvascular and spatial memory deficits in the absence of neurodegeneration 
(Troen et al., 2008). Similarly, a study conducted in humans showed a direct association 
between hyperhomocysteinemia and cognitive deficits in the absence of mediation 
through white matter burden (Dufouil, Alpérovitch, Ducros, & Tzourio, 2003).  
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Combined, these studies suggest an etiology that is distinct from AD. Additional studies 
have demonstrated that the risk of having Hcy values in the upper tertile among persons 
with VaD after adjustment for demographic, nutrition, and vascular factors is higher, 
albeit not significantly (odds ratio, OR = 4.9) than that of persons with mild cognitive 
impairment (OR = 2.0), AD (OR = 2.0 – 3.7), AD plus VaD (OR = 4.3), or histologically 
confirmed AD (OR = 4.5). Those findings suggest that cerebrovascular causes are not 
limited to the development of VaD (Clarke et al., 1998; McIlroy, Dynan, Lawson, 
Patterson, & Passmore, 2002; Quadri et al., 2004). Some studies, however, showed no 
association between hyperhomocysteinemia and incident VaD. For example, in a 
prospective study of Italian elders hyperhomocysteinemia predicted the development of 
AD but not VaD after controlling for additional vascular risk factors, while elevated CRP 
was predictive of the development of VaD but not AD (Ravaglia et al., 2007).  
Elevated CRP and Hcy and Their Effects on the Central Nervous System 
Neuroimaging studies lend further support to the notion that elevations in either 
CRP or Hcy are associated with changes in the brain. Lacunar infarcts are linked to 
inflammatory markers independent of traditional cardiovascular risk factors (Hoshi et al., 
2005). Higher levels of circulating CRP have been associated with more severe 
periventricular and subcortical white matter lesions at baseline, as well as greater  white 
matter hyperintensity (WMH) expansion at follow-up (van Dijk et al., 2005). CRP is a 
graded risk factor for the presence of both white matter lesions and brain infarcts 
(Fornage et al., 2008; Hoshi et al., 2005), particularly among women (Sachdev et al., 
2006).  
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Similarly, studies have shown an association between total serum Hcy levels and 
WMH volume (Wright et al., 2005) as well as the number and severity of silent brain 
infarcts and white matter lesions (de Lau, Smith, Refsum, Johnston, & Breteler, 2009; 
Polyak et al., 2003; Prins et al., 2002; Sachdev, 2004; Sachdev et al., 2003; Vermeer et 
al., 2002; Wong et al., 2006), though the effect may be stronger for men (Sachdev et al., 
2004). Elevated Hcy has also been associated with medial temporal (Williams, Pereira, 
Budge, & Bradley, 2002; den Heijer et al., 2003; Refsum et al., 2004) and general 
cortical (Prins et al., 2002; Sachdev et al., 2003) atrophy. Moreover, high levels of total 
serum Hcy in combination with low levels of serum vitamin B12 and folate have been 
associated with atrophy and histological changes in persons diagnosed with AD (Clarke 
et al., 1998). However, low levels of vitamin B12 (Vogiatzoglou et al., 2008) and folate 
(Snowdon, Tully, Smith, Riley, & Markesbery, 2000) are independently associated with 
brain volume loss and severity of brain atrophy. In addition, several studies have shown 
elevations in either CRP or Hcy are unrelated to the presence and severity of lacunar 
infarcts and white matter disease burden, or whole brain volume (Dufouil, et al., 2003; 
Gunstad et al., 2006; Longstreth et al., 2004; Quadri et al., 2004). Thus, the relationship 
between CRP and Hcy levels and brain structure is far from fully understood.    
Elevated CRP and Hcy and Cognitive Performance 
Elevations in CRP and Hcy have been associated with an increased incidence of 
AD and VaD (Schmidt et al., 2002), which exhibit different patterns of cognitive deficits. 
In AD, declarative memory declines are predominant from the start. Conversely, in VaD, 
a relative sparing of memory is accompanied by executive dysfunction (Pantoni, 
Poggesi, & Inzitari, 2009; Román, 2005; Solfrizzi et al. 2006). It is not surprising then 
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that numerous studies have examined the relationship between elevations in blood 
biomarker levels and cognitive performance across a plethora of cognitive domains from 
crude indices of global cognition (e.g., Mini Mental State Exam; MMSE) to higher-order 
processing (e.g., executive functions), with deficits observed in many of these.  
With regards to CRP, the findings are mixed, with the majority of studies showing 
either no relationship or a negative correlation. However, most studies have examined 
older adults within a relatively narrow age range, with very few studies examining a 
lifespan sample. A summary of studies conducted in cross-sectional populations can be 
found in Table 1, and longitudinal studies in Table 2. Similarly, elevated levels of Hcy 
have been linked to poorer cognitive outcomes in some studies, whereas others have 
found no association, and still others have shown both no association and a negative 
association for the same domain depending on the type of neuropsychological tests 
used for assessment. The reasons for the latter discrepancy are unclear and may 
include questionable validity of some cognitive measures. Finally, one study has shown 
a positive effect of elevated Hcy levels among females with eating disorders (Freiling et 
al., 2005). A summary of findings from cross-sectional studies can be found in Table 3, 
longitudinal studies in Table 4, and placebo-controlled and parallel-group trials in Table 
5. 
It has been suggested that the potential for cognitive decline is heightened by 
combined effects of CRP and Hcy (Gunstad et al., 2006). However, few studies have 
examined both biomarkers in conjunction with measures of cognitive performance. 
Moreover, the majority of these studies found no relation between CRP and Hcy levels,  
thereby precluding analysis of their cumulative effects (Fischer et al., 2006; Gunstad et
11 
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.
,
 2003
a
re
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e
nts
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n
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ve
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ag
e
,
 se
x
,
 ed
u
catio
n
,
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ry
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n
ce
r
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,
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ru
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glu
co
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R
a
vaglia
 et
 al
.
,
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glob
al
 cog
nitio
n
 (
-)
cog
nitively
 inta
ct
 re
sid
e
nts
 of
 C
o
n
selice
 o
ve
r
 
65
 ye
a
rs
ag
e
,
 ed
u
catio
n
,
 se
x
,
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a
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rin
oge
n
,
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uko
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 co
u
nt
,
 se
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m
 
alb
u
m
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,
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I
,
 n
u
m
b
e
r
 of
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m
o
rbid
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,
 ed
e
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a
w
cro
ss
 et
 al
.
,
 2007
psych
o
m
oto
r
 sp
e
ed
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,
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e
cla
rative
 
m
e
m
o
ry
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,
 e
xe
cutive
 fu
n
ctio
n
s
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atie
nts
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sis
ag
e
Sh
u
ca
rd
 et
 al
.
,
 2007
p
re
m
o
rbid
 intellig
e
nce
 (0)
,
 atte
ntio
n
 (
-)
fe
m
ale
 p
atie
nts
 with
 syste
m
ic
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u
s
 
e
ryth
e
m
ato
sus
n
o
n
e
S
u
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 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (
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,
 p
sych
o
m
oto
r
 sp
e
ed
 
(0)
,
 d
e
cla
rative
 m
e
m
o
ry
 (0)
,
 e
xe
cutive
 
fu
n
ctio
n
s
 (0)
o
utp
atie
nts
 with
 diab
ete
s
 ag
ed
 65
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a
rs
n
o
n
e
W
e
u
ve
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
,
 d
e
cla
rative
 m
e
m
o
ry
 
(0)
,
 e
xe
cutive
 fu
n
ctio
n
s
 (0)
w
o
m
e
n
 h
ealth
 p
rofe
ssio
n
als
 o
ve
r
 66
 ye
a
rs
ag
e
,
 ed
u
catio
n
,
 in
co
m
e
,
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b
etw
e
e
n
 testing
,
 sm
oking
,
 alcoh
ol,
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 a
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,
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I
,
 H
BP
,
 
ch
ole
ste
rol
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,
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ride
s
,
 H
RT
 
m
eds
W
right
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
stroke
-fre
e
 re
sid
e
nts
 of
 M
a
nh
atta
n
ag
e
,
 se
x
,
 ra
ce
,
 ed
u
catio
n
,
 H
BP
,
 
C
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,
 sm
oking
,
 tH
cy
,
 diab
ete
s
,
 
BM
I
,
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ol
N
ote
:
 Th
e
 dire
ctio
n
 of
 th
e
 a
sso
ciatio
n
 betw
ee
n
 h
eighte
n
ed
 C
-re
active
 p
rotein
 le
vels
 a
nd
 sp
e
cific
 cog
nitive
 do
m
ain
s
 is
 indicated
 by
 the
 sig
n
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 (
-)
 is
 a
 
n
eg
ative
 associatio
n
 a
nd
 (0)
 is
 no
 a
sso
ciatio
n
.
 C
o
va
riates
 a
re
 listed
 in
 the
 o
rd
e
r
 indicated
 by
 the
 individ
u
al
 studies
.
 Abb
re
viatio
ns:
 H
BP
 
=
 high
 blo
od
 
p
re
ssu
re/
 hype
rte
n
sio
n
,
 CVD
 
=
 ca
rdio
va
scula
r
 dise
a
se
,
 B6
 
=
 vita
m
in
 B6
,
 B12
 
=
 vita
m
in
 B12
,
 G
DS
 
=
 G
e
riatric
 D
ep
re
ssio
n
 S
cale
,
 AD
 
=
 Alzh
eim
e
r
's
 
disea
se
,
 V
aD
 
=
 vascula
r
 d
e
m
e
ntia
,
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I
 
=
 b
ody
 m
ass
 ind
e
x
,
 H
RT
 
=
 h
o
rm
o
n
e
 repla
ce
m
e
nt
 th
e
rapy
,
 tH
cy
 
=
 total
 h
o
m
o
cystein
e
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.
,
 2008
glob
al
 cog
nitio
n
 (
-)
,
 visuospatial
 
ability
 (0)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 
reaso
ning
 (
-)
high
-fu
nctio
ning
 pe
rso
ns
 aged
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-79
 yea
rs
 at
 
b
aseline
no
ne
Blasko
 et
 al
.
,
 2007
glob
al
 cog
nitio
n
 (0)
o
utpatie
nts
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 p
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no
ne
D
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 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (0)
,
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m
oto
r
 
spe
ed
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,
 d
ecla
rative
 m
e
m
o
ry
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,
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ning
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p
a
rticipa
nts
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A
m
e
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m
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 yea
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e
,
 se
x
,
 ed
ucatio
n
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rd
a
no
va
 et
 al
.
,
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glob
al
 cog
nitio
n
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oto
r
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 d
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ry
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 et
 al
.
,
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glob
al
 cog
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 d
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ed
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.
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glob
al
 cog
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 et
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,
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m
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 reaso
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cutive
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 p
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 al
.
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al
 cog
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 p
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 et
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.
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 L
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x
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 m
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al., 2006; Ravaglia et al., 2005; Silbert, Evered, Scott, McCutcheon, & Jamrozik, 2008). 
To date, only one study has found a combined negative effect. In the Longitudinal Aging 
Study Amsterdam, the potential modifying effect of inflammatory markers on the 
relationship between tHcy and cognitive function was assessed. Persons with the 
highest tertile of CRP who also had a high level of tHcy performed the worst on delayed 
recall of a verbal learning task. CRP also had a modifying effect on longitudinal rate of 
decline for processing speed, such that persons with a high tHcy showed the fastest 
rate of decline for the lowest and middle tertiles of CRP (van den Kommer et al., in 
press). 
Genetic Regulation of CRP and Hcy in CVD 
Blood levels of both CRP and Hcy depend in part on genetic factors. However 
little is known about how specific SNPs influence inflammation and its effects on 
cognition. The CRP gene has been localized to the proximal long arm of chromosome 1 
in the q21-q23 region, and contains two coding regions (exons 1 and 2) consisting of a 
204-amino acid chain and separated by a single 280-base pair intron encoding a 
dinucleotide repeat (GT), and flanked by a 5’- and 3’-untranslated region on either side 
(Danik & Ridker, 2007; Hage & Szalai, 2007; Lee et al., 2009). The CRP gene is 
polymorphic and it has over 40 SNPs forming 29 different haplotypes, with the largest 
haplotypic diversity occurring in African Americans (Crawford et al., 2006; Hage & 
Szalai, 2007). With the exception of exon 1, SNPs have been identified in all other 
areas of the CRP gene. Although many of these have been shown to affect baseline 
blood levels of CRP, few have been linked to cardiovascular risk, and only one of them 
is functional: the triallelic C>T>A polymorphism (rs3091244), occurring at two different
16 
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 m
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w
,
 BM
I
Alm
eid
a
 et
 al
.
,
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glob
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nitio
n
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,
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 et
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.
,
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.
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 m
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o
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I
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.
,
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 cog
nitio
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e
B
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 et
 al
.
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.
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ve
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 al
.
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e
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.
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 cog
nitio
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,
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op
a
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 et
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.
,
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glob
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 cog
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,
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,
 de
cla
rative
 
m
e
m
o
ry
 (0)
,
 e
xecutive
 fu
nctio
n
s
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m
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n
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e
m
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m
m
u
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 elde
rs
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ve
r
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 ye
a
rs
 
age
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 se
x
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u
catio
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 dep
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 b
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.
,
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p
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 d
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u
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n
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ulu
s
 et
 al
.
,
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e
m
e
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ve
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a
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o
n
e
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,
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p
re
m
o
rbid
 intellig
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oto
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ra
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 d
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,
 p
sycho
m
oto
r
 spe
ed
 
 
 
(
-)
,
 visu
osp
atial
 ability
 (
-)
,
 de
cla
rative
 
m
e
m
o
ry
 (0)
,
 rea
so
ning
 (
-)
,
 e
xecutive
 
fu
n
ctio
n
s
 (
-)
co
m
m
u
nity
 d
w
elle
rs
 ag
ed
 26
-98
 ye
a
rs
age
,
 se
x
,
 ed
u
catio
n
,
 p
ra
ctice
 effe
cts
,
 
eth
nicity
,
 folate
,
 B6
,
 B12
,
 C
VD
 risk
 
p
rofile
,
 C
VD
Elias
 et
 al
.
,
 2008
glob
al
 cog
nitio
n
 (
-)
,
 p
sycho
m
oto
r
 spe
ed
 
(0)
,
 visuo
sp
atial
 ability
 (0)
,
 d
ecla
rative
 
m
e
m
o
ry
 (0)
,
 rea
so
ning
 (
-)
,
 e
xecutive
 
fu
n
ctio
n
s
 (
-)
co
m
m
u
nity
 d
w
elle
rs
 ag
ed
 26
-98
 ye
a
rs
age
,
 se
x
,
 ed
u
catio
n
,
 p
ra
ctice
 effe
cts
,
 
eth
nicity
,
 folate
,
 B6
,
 B12
,
 C
VD
 risk
 
p
rofile
,
 C
VD
18 
 
 
T
able
 3
 co
nt
.
A
utho
r(s)
D
o
m
ain
s
 A
ssessed
S
a
m
ple
 D
e
scriptio
n
C
o
va
riates
F
e
ng
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
,
 psycho
m
oto
r
 sp
eed
 
 
 
(
-)
,
 m
a
n
u
al
 d
e
xte
rity
 (
-)
,
 visu
ospatial
 
ability
 (0)
,
 co
n
stru
ctio
n
 p
ra
xis
 (
-)
,
 
atte
ntio
n
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (0)
ra
nd
o
m
 selectio
n
 of
 p
a
rticip
a
nts
 fro
m
 
Singap
o
re
 Lo
ngitudinal
 Ageing
 Study
 o
ve
r
 
55
 yea
rs
age
,
 se
x
,
 ed
u
catio
n
Fische
r
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
inhabita
nts
 of
 Vie
n
na
 aged
 75
 yea
rs
n
o
n
e
F
o
rti
 et
 al
.
,
 2001
glob
al
 cog
nitio
n
 (
-)
,
 la
ng
uage
 (
-)
,
 
visu
osp
atial
 ability
 (0)
,
 co
n
stru
ctio
n
 p
ra
xis
 
(0)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 re
aso
ning
 
(0)
,
 e
xecutive
 fu
nctio
ns
 (0)
ra
nd
o
m
 selectio
n
 of
 p
a
rticip
a
nts
 fro
m
 
C
o
nselice
 Study
 o
ve
r
 65
 yea
rs
n
o
n
e
F
reiling
 et
 al
.
,
 2005
p
re
m
o
rbid
 intellig
e
n
ce
 (0)
,
 p
sych
o
m
oto
r
 
sp
eed
 (0)
,
 co
n
structio
n
 p
ra
xis
 (0)
,
 
atte
ntio
n
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (+)
,
 
e
xecutive
 fu
nctio
n
s
 (0)
p
atie
nts
 with
 a
 diag
n
osis
 of
 a
n
o
re
xia
 o
r
 
b
ulim
ia
 ne
rvosa
 aged
 18
-51
 yea
rs
IC
D
-10
 diag
n
osis
,
 ag
e
,
 BM
I
,
 full
 scale
 
IQ
G
a
rcia
 et
 al
.
,
 2004a
glob
al
 cog
nitio
n
 (0)
,
 de
cla
rative
 m
e
m
o
ry
 
(0)
,
 e
xecutive
 fu
nctio
ns
 (
-)
co
m
m
u
nity
-d
w
elling
 volu
nte
e
rs
 o
ve
r
 65
 
ye
a
rs
age
,
 ed
ucatio
n
,
 se
x
,
 m
ethylcitric
 a
cid
,
 
cre
atinine
G
o
rg
o
n
e
 et
 al
.
,
 2009
glob
al
 cog
nitio
n
 (
-)
p
atie
nts
 with
 cog
nitive
 im
p
airm
e
nt
 a
nd
 
m
atch
ed
 co
ntrols
age
G
u
nstad
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
,
 psycho
m
oto
r
 sp
eed
 
(0)
,
 m
a
n
ual
 d
e
xte
rity
 (0)
,
 visuo
sp
atial
 
ability
 (0)
,
 co
n
stru
ctio
n
 p
ra
xis
 (0)
,
 
atte
ntio
n
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (0)
,
 
reaso
ning
 (0)
,
 e
xecutive
 fu
nctio
n
s
 (0)
p
e
rso
ns
 
 w
ith
 a
 do
cu
m
e
nted
 histo
ry
 of
 
C
VD
 ag
ed
 55
-85
 ye
a
rs
age
,
 se
x
,
 H
BP
,
 diab
etes
,
 sm
oking
,
 B6
,
 
B12
,
 folic
 a
cid
H
a
apa
nie
m
i
 et
 al
.
,
 2007
glob
al
 cog
nitio
n
 (
-)
individ
u
als
 with
 first
-e
ve
r
 ische
m
ic
 stroke
n
o
n
e
H
a
ssin
-B
ae
r
 et
 al
.
,
 2006
gloabal
 cog
nitio
n
 (0)
,
 p
sych
o
m
oto
r
 spe
ed
 
(0)
,
 atte
ntio
n
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (0)
,
 
w
o
rking
 m
e
m
o
ry
 (0)
,
 e
xe
cutive
 fu
n
ctio
ns
 
(0)
p
aitie
nts
 with
 PD
age
,
 d
u
ratio
n
 of
 PD
,
 se
x
H
e
ngste
rm
a
n
n
 et
 al
.
,
 2009
glob
al
 cog
nitio
n
 (0)
g
e
riatric
 patie
nts
 with
 a
cute
 m
edical
 
co
nditio
n
s
 o
ve
r
 65
 yea
rs
n
o
n
e
H
e
stad
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (0)
reside
nts
 of
 H
ed
m
a
rk
 o
ve
r
 80
 ye
a
rs
n
o
n
e
19 
 
T
able
 3
 co
nt
.
A
utho
r(s)
D
o
m
ain
s
 A
ssessed
S
a
m
ple
 D
e
scriptio
n
C
o
va
riates
Iriza
rry
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (
-
 fo
r
 PD/0
 oth
e
rs)
p
atie
nts
 with
 M
C
I
,
 AD
,
 PD
,
 o
r
 ce
reb
ral
 
a
m
yloid
 a
ngiopathy
 a
nd
 their
 ca
regive
rs
age
,
 le
vod
opa
 use
Je
n
se
n
 et
 al
.
,
 1998
la
ng
uage
 (0)
,
 visuo
spatial
 ability
 (
-)
,
 
atte
ntio
n
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (
-/0)
,
 
reaso
ning
 (
-)
,
 w
o
rking
 m
e
m
o
ry
 (0)
reside
nts
 of
 L
u
nd
 ag
ed
 80
 ye
a
rs
n
o
n
e
Leblh
ub
e
r
 et
 al
.
,
 2000
glob
al
 cog
nitio
n
 (
-)
p
atie
nts
 with
 p
robable
 AD
,
 VD
,
 a
nd
 ag
e
-
m
atch
ed
 co
ntrols
n
o
n
e
Leh
m
a
n
n
 et
 al
.
,
 1999
glob
al
 cog
nitio
n
 (
-)
p
e
rso
ns
 with
 subjective
 m
e
m
o
ry
 
co
m
plaints
 o
ve
r
 50
 ye
a
rs
n
o
n
e
Le
wis
 et
 al
.
,
 2005a
glob
al
 cog
nitio
n
 (0)
,
 rea
so
ning
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (0)
elde
rs
 recruited
 fro
m
 se
nio
r
 ce
nte
rs
cre
atinine
M
a
nd
e
rs
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
institutio
n
alized
 elde
rly
 with
 cog
nitive
 
d
ete
rio
ratio
n
age
M
a
re
ngo
ni
 et
 al
.
,
 2004
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 ad
m
itted
 to
 a
cute
 ge
riatric
 w
a
rd
 
o
ve
r
 65
 yea
rs
age
,
 se
x
,
 ed
u
catio
n
,
 creatinin
e
,
 
alb
u
m
in
,
 B12
,
 folate
,
 disability
,
 
ath
e
roscle
rotic
 disea
se
M
cC
addo
n
 et
 al
.
,
 2003
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 with
 p
rim
a
ry
 dege
ne
rative
 
d
e
m
e
ntia
 of
 Alzheim
e
r
 typ
e
 a
nd
 m
atched
 
co
ntrols
glutathio
n
e
,
 cysteine
M
ille
r
 et
 al
.
,
 2003
glob
al
 cog
nitio
n
 (
-)
,
 visu
osp
atial
 ability
 
 
 
 
 
(
-)
,
 atte
ntio
n
 (
-)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 
reaso
ning
 (
-/0)
co
m
m
u
nity
-d
w
elling
 L
atino
s
 o
ve
r
 60
 yea
rs
folate
,
 B12
,
 creatinin
e
,
 age
,
 se
x
,
 
ed
u
catio
n
,
 a
ccultu
ratio
n
M
izrahi
 et
 al
.
,
 2003
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 with
 p
robable
 AD
 a
nd
 m
atched
 
co
ntrols
n
o
n
e
M
o
rris
 et
 al
.
,
 2001
d
ecla
rative
 m
e
m
o
ry
 (
-)
p
e
rso
ns
 fro
m
 th
e
 seco
nd
 w
a
ve
 of
 
N
H
AN
ES
 o
ve
r
 60
 ye
a
rs
se
x
,
 ag
e
,
 race
,
 in
co
m
e
,
 folate
O
sh
e
r
 et
 al
.
,
 2008
p
sycho
m
oto
r
 spe
ed
 (0)
,
 visuo
spatial
 
ability
 (0)
,
 atte
ntio
n
 (0)
,
 decla
rative
 
m
e
m
o
ry
 (0)
,
 e
xecutive
 fu
nctio
n
s
 (
-/0)
e
uthym
ic
 typ
e
 1
 bipola
r
 diso
rd
e
r
 
o
utpatie
nts
 a
nd
 co
ntrols
age
20 
 
 
T
able
 3
 co
nt
.
 
A
utho
r(s)
D
o
m
ain
s
 A
ssessed
S
a
m
ple
 D
e
scriptio
n
C
o
va
riates
O
'S
uilleabhain
 et
 al
.
,
 2004
glob
al
 cog
nitio
n
 (0)
,
 m
a
n
u
al
 d
e
xte
rity
 (
-)
,
 
co
nstructio
n
 p
ra
xis
 (
-)
,
 atte
ntio
n
 (0)
,
 
d
ecla
rative
 m
e
m
o
ry
 (0)
,
 w
o
rking
 m
e
m
o
ry
 
(0)
,
 e
xecutive
 fu
nctio
ns
 (
-/0)
p
atie
nts
 with
 diag
n
osis
 of
 PD
 ag
ed
 35
-90
 
ye
a
rs
le
vod
op
a
 do
se
,
 age
,
 se
x
,
 d
u
ratio
n
 of
 
PD
O
ze
r
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (
-)
,
 visu
osp
atial
 ability
 
 
 
 
 
(
-/0)
,
 co
nstru
ctio
n
 p
ra
xis
 (0)
,
 d
ecla
rative
 
m
e
m
o
ry
 (0)
,
 rea
so
ning
 (0)
,
 e
xecutive
 
fu
n
ctio
n
s
 (
-/0)
p
atie
nts
 with
 idiopathic
 PD
 a
nd
 m
atch
ed
 
co
ntrols
n
o
n
e
P
a
ulio
nis
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (0)
reside
nts
 of
 a
 lo
ng
-te
rm
 ca
re
 facility
n
o
n
e
P
rins
 et
 al
.
,
 2002
glob
al
 cog
nitio
n
 (
-)
,
 p
sycho
m
oto
r
 spe
ed
 
 
 
 
(
-)
,
 d
ecla
rative
 m
e
m
o
ry
 (
-)
co
m
m
u
nity
 d
w
elle
rs
 ag
ed
 60
-90
 ye
a
rs
age
,
 se
x
,
 ed
u
catio
n
,
 C
ESD
 sco
re
,
 
cre
atinine
,
 alcoh
ol,
 sm
oking
Q
uad
ri
 et
 al
.
,
 2004
glob
al
 cog
nitio
n
 (
-)
p
e
rso
ns
 with
 AD
,
 V
aD
 o
r
 h
ealthy
 co
ntrols
 
o
ve
r
 60
 yea
rs
n
o
n
e
R
a
ede
r
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 ad
m
itted
 fo
r
 a
cute
 
m
edical/su
rgical
 co
nditio
ns
n
o
n
e
R
a
m
os
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (0)
,
 de
cla
rative
 m
e
m
o
ry
 
(0)
 
co
m
m
u
nity
-d
w
elling
 L
atino
s
 o
ve
r
 60
 yea
rs
R
BC
 folate
,
 B12
,
 creatinin
e
,
 ag
e
,
 se
x
,
 
ed
u
catio
n
,
 a
ccultu
ratio
n
,
 C
ESD
 sco
re
 
R
a
vaglia
 et
 al
.
,
 2003b
glob
al
 cog
nitio
n
 (
-)
cog
nitively
 inta
ct
 re
side
nts
 of
 C
o
nselice
 
o
ve
r
 65
 yea
rs
age
,
 ed
ucatio
n
,
 in
co
m
e
,
 creatinin
e
,
 B
 
vita
m
in
,
 active
 life
style
,
 coffee
,
 m
e
at
 
co
nsu
m
ptio
n
R
a
vaglia
 et
 al
.
,
 2004b
glob
al
 cog
nitio
n
 (
-/0)
,
 la
ng
u
age
 (0)
,
 
visu
osp
atial
 ability
 (0)
,
 co
n
stru
ctio
n
 p
ra
xis
 
(0)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 re
aso
ning
 
(0)
,
 e
xecutive
 fu
nctio
ns
 (
-)
ra
nd
o
m
 selectio
n
 of
 p
a
rticip
a
nts
 fro
m
 
C
o
nselice
 study
 o
ve
r
 65
 yea
rs
 
n
o
n
e
R
a
vaglia
 et
 al
.
,
 2000
a
glob
al
 cog
nitio
n
 (0)
ce
nte
n
a
ria
ns
 living
 in
 tw
o
 p
ro
vince
s
 of
 
Italy
n
o
n
e
R
a
vaglia
 et
 al
.
,
 2000b
glob
al
 cog
nitio
n
 (0)
,
 la
ng
u
ag
e
 (0)
,
 
visu
osp
atial
 ability
 (0)
,
 co
n
stru
ctio
n
 p
ra
xis
 
(0)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 re
aso
ning
 
(0)
,
 e
xecutive
 fu
nctio
ns
 (0)
cog
nitively
 inta
ct
 re
side
nts
 of
 C
o
nselice
 
o
ve
r
 65
 yea
rs
n
o
n
e
21 
 
 
T
able
 3
 co
nt
.
A
utho
r(s)
D
o
m
ain
s
 A
ssessed
S
a
m
ple
 D
e
scriptio
n
C
o
va
riates
R
a
vaglia
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (
-)
cog
nitively
 inta
ct
 re
side
nts
 of
 C
o
nselice
 
o
ve
r
 65
 yea
rs
age
,
 ed
ucatio
n
,
 se
x
,
 pla
sm
a
 
fib
rinoge
n
,
 le
ukocyte
 co
u
nt
,
 se
ru
m
 
alb
u
m
in
 BM
I
,
 n
u
m
be
r
 of
 co
m
o
rbid
 
disea
se
s
,
 ede
ntulism
R
iggs
 et
 al
.
,
 1996
p
re
m
o
rbid
 intellig
e
n
ce
 (0)
,
 co
n
structio
n
 
p
ra
xis
 (
-/0)
,
 atte
ntio
n
 (0)
,
 d
ecla
rative
 
m
e
m
o
ry
 (0)
,
 w
o
rking
 m
e
m
o
ry
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (0)
p
a
rticip
a
nts
 of
 VA
 N
o
rm
ative
 Aging
 Study
 
aged
 54
-81
 yea
rs
n
o
n
e
R
obbins
 et
 al
.
,
 2005
glob
al
 cog
nitio
n
 (
-
 fo
r
 diabetics/0
 oth
e
rs)
co
m
m
u
nity
-d
w
elling
 d
e
m
e
ntia
 a
nd
 stroke
-
fre
e
 pe
rso
n
s
,
 so
m
e
 diab
etic
age
,
 ed
ucatio
n
,
 se
x
,
 folate
,
 B6
,
 B12
,
 
cig
a
rette
,
 SBP
,
 re
nal
 dysfu
n
ctio
n
,
 
ch
ole
ste
rol,
 coffee
,
 dep
re
ssed
 m
o
od
R
od
rig
ue
z
-O
ro
z
 et
 al
.
,
 2009
glob
al
 cog
nitio
n
 (0)
,
 psycho
m
oto
r
 sp
eed
 
(0)
,
 co
nstru
ctio
n
 p
ra
xis
 (0)
,
 atte
ntio
n
 (0)
,
 
d
ecla
rative
 m
e
m
o
ry
 (0)
,
 rea
so
ning
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (0)
p
atie
nts
 with
 PD
 o
ve
r
 60
 ye
a
rs
 
age
,
 B12
,
 B6
,
 folate
S
achd
e
v
 et
 al
.
,
 2003
la
ng
uage
 (0)
,
 psych
o
m
oto
r
 sp
eed
 (
-)
,
 
atte
ntio
n
 (
-)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (
-)
p
atie
nts
 with
 rece
nt
 isch
e
m
ic
 stroke
 a
nd
 
h
ealthy
 co
ntrols
 ag
ed
 55
-87
 ye
a
rs
age
,
 folate
,
 cre
atinine
S
achd
e
v
 et
 al
.
,
 2004
glob
al
 cog
nitio
n
 (
-)
,
 p
sycho
m
oto
r
 spe
ed
 
(0)
,
 m
a
n
ual
 d
e
xte
rity
 (
-)
,
 d
ecla
rative
 
m
e
m
o
ry
 (
-)
co
m
m
u
nity
-d
w
elling
 re
side
nts
 aged
 60
-64
 
ye
a
rs
age
,
 se
x
,
 folate
,
 B12
,
 creatinin
e
,
 H
BP
,
 
sm
oking
,
 diabetes
S
achd
e
v
,
 2004
 (P
ath)
glob
al
 cog
nitio
n
 (0)
,
 psycho
m
oto
r
 sp
eed
 
(0)
,
 m
a
n
ual
 d
e
xte
rity
 (0)
,
 de
cla
rative
 
m
e
m
o
ry
 (0)
co
m
m
u
nity
-d
w
elling
 re
side
nts
 aged
 60
-64
 
ye
a
rs
age
,
 se
x
,
 folate
,
 B12
,
 creatinin
e
S
achd
e
v
,
 2004
 (Syd
ney)
la
ng
uage
 (
-)
,
 psycho
m
oto
r
 sp
eed
 (0)
,
 
atte
ntio
n
 (
-)
,
 de
cla
rative
 m
e
m
o
ry
 (0)
,
 
e
xecutive
 fu
nctio
n
s
 (
-)
p
atie
nts
 with
 rece
nt
 isch
e
m
ic
 attack
 a
nd
 
h
ealthy
 co
ntrols
 ag
ed
 55
-87
 ye
a
rs
age
,
 folate
,
 cre
atinine
S
ala
 et
 al
.
,
 2008
glob
al
 cog
nitio
n
 (0)
,
 psycho
m
oto
r
 sp
eed
 
(0)
,
 visuo
sp
atial
 ability
 (0)
,
 co
n
structio
n
 
p
ra
xis
 (0)
,
 d
ecla
rative
 m
e
m
o
ry
 (0)
,
 
reaso
ning
 (0)
,
 e
xecutive
 fu
nctio
n
s
 (0)
p
atie
nts
 with
 subje
ctive
 m
e
m
o
ry
 
co
m
plaints
,
 M
C
I
,
 AD
,
 V
aD
age
,
 ed
ucatio
n
,
 se
x
,
 creatinin
e
,
 B12
,
 
folate
22 
 
 
T
able
 3
 co
nt
.
A
utho
r(s)
D
o
m
ain
s
 A
ssessed
S
a
m
ple
 D
e
scriptio
n
C
o
va
riates
S
ch
afe
r
 et
 al
.
,
 2005
p
sycho
m
oto
r
 spe
ed
 (
-)
,
 m
a
n
u
al
 d
e
xte
rity
 
 
 
(
-)
,
 co
nstructio
n
 p
ra
xis
 (
-)
,
 de
cla
rative
 
m
e
m
o
ry
 (
-)
,
 rea
so
ning
 (
-)
,
 e
xecutive
 
fu
n
ctio
n
s
 (
-)
reside
nts
 of
 B
altim
o
re
 aged
 50
-70
 yea
rs
ra
ce
,
 te
ste
r
,
 sm
oking
,
 alcohol,
 BM
I
,
 
ch
ole
ste
rol
Ste
w
a
rt
 et
 al
.
,
 2002
glob
al
 cog
nitio
n
 (
-)
p
e
rso
ns
 of
 Africa
n
-C
a
ribbea
n
 he
ritage
 
aged
 55
-75
 yea
rs
 
age
,
 occupatio
n
,
 H
BP
,
 diabete
s
,
 
physicl
 a
ctivity
,
 choleste
rol,
 
triglyce
ride
s
,
 fib
rinoge
n
,
 folate
,
 BM
I
,
 
w
aist/hip
 ratio
,
 sm
oking
,
 alcoh
ol,
 
M
M
SE
 sco
re
 belo
w
 20
T
ab
et
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 with
 AD
 living
 with
 a
 ca
re
r
 in
 the
 
co
m
m
u
nity
n
o
n
e
T
assin
o
 et
 al
.
,
 2009
glob
al
 cog
nitio
n
 (
-)
lo
w
 in
co
m
e
 B
ra
zilia
n
s
 o
ve
r
 60
 yea
rs
ed
u
catio
n
,
 age
,
 folic
 acid
T
ay
 et
 al
.
,
 2006
glob
al
 cog
nitio
n
 (0)
p
atie
nts
 p
ost
 first
 stroke
ed
u
catio
n
,
 age
,
 stroke
 subtype
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sites -286 and -390 (Hage & Szalai, 2007). Genotypic variants in the triallelic C>T>A 
polymorphism have been differentially linked with higher CRP levels among non-
Hispanic blacks (AA, TT, AT, CT) and Hispanics (TT, CT) compared to the referent CC 
genotype. Conversely, among non-Hispanic whites, the AA genotype has been 
associated with incident coronary heart disease, but not baseline CRP levels (Crawford 
et al., 2006).  
With regards to Hcy, several candidate genes which encode the enzymes 
involved in Hcy regulation have been examined including cystathionine β-synthase 
(CBS), methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), 
and methionine synthase reductase (MTRR), of which the most extensively studied is 
MTHFR (Kluijitmans et al., 2003; Trabetti, 2008). MTHFR catalyses the irreversible 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which serves 
as a methyl donor in the reaction converting Hcy to methionine (Trabetti, 2008). A 
thermolabile variant in MTHFR positioned at 1p36.3 and caused by a mutation in the C 
to T transition at base pair 677 (exon 4) leading to an amino acid substitution (alanine to 
valine) at codon 222 has been associated with decreased enzymatic activity and 
consequently, increased Hcy concentrations (Kang, Zhou, Kong, Kowalisyn, & 
Strokosch, 1988). Homozygosity for the T genotype tends to be associated with the 
highest Hcy levels (Albert et al., 2009; Dedoussis et al., 2005). However, sex 
differences in the effects of that SNP have been reported. The association between 
MTHFR 677T allele and Hcy levels is particularly strong among males (Kluijtmans et al., 
2003), and is not related to Hcy levels among black, Asian, or Hispanic women (Albert 
et al., 2009). Consistent evidence linking the MTHFR 677C>T to vascular risk is lacking, 
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and meta-analyses have produced conflicting results. In one study, the TT variant was 
not associated with incremental risk for coronary heart disease (Lewis, Ebrahim, & 
Davey Smith, 2005b), whereas another showed a 16% greater risk among persons with 
the TT variant compared to persons with the CC variant (Klerk et al., 2002). Notably, T 
carriers are disproportionately represented among persons with VaD, suggesting the 
link is not spurious (McIlroy, et al., 2002). 
 Genetic Regulation of CRP and Hcy in Cognition  
With regards to cognition, few polymorphisms of the CRP gene have been 
examined for a role in cognitive decline. However, because systemic inflammation has 
been implicated in the development of AD and VaD, and elevations in CRP are related 
to white matter lesions and brain infarcts, there is sufficient reason to suspect cognitive 
decline is under genetic regulation through the CRP gene. To date, five studies have 
examined elevations in CRP within the context of genetic regulation (Dik et al., 2005; 
Haan, Aiello, West, & Jagust, 2008; Mathew et al., 2007; Schram et al., 2007; Szwast et 
al., 2007), all but one of which (Mathew et al., 2007) examined apolipoprotein E 
(ApoEε2/3/4) and not CRP polymorphisms. In the latter, two CRP SNPs (2147 C>T, 
1059 G>C) were examined in the context of post-operative cognitive deficits following a 
coronary artery bypass graft, of which only the less prevalent SNP 1059 G>C was 
associated with cognitive deficits post-surgery (Mathew et al., 2007).  
Conversely, several studies have examined cognitive outcomes in the context of 
MTHFR with equivocal results. Some reported no cognitive reduction in T carriers 
(Bottiglieri et al., 2001; Flicker et al., 2004; Gussekloo et al., 1999; Matsui et al., 2001; 
Nurk et al., 2005; Ravaglia et al., 2004a; Rodriguez-Oroz et al., 2009), even in the 
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presence of higher Hcy levels (Almeida et al., 2005; Bathum et al., 2007; Camicioli, 
Bouchard, & Sommerville, 2009; de Lau et al., in press; Russo et al., 2008). Other 
studies however have found an association between the T allele and reduced 
performance among older women (Elkins et al., 2007), hypertensives (Deshmukh et al., 
2009), depressed persons (Naismith et al., 2002), schizophrenics (Roffman et al., 2007; 
Roffman et al., 2008), and persons with a diagnosis of mild cognitive impairment or 
dementia (Gorgone et al., 2009; Religa et al., 2003; Yoo, Choi, & Kang, 2000). Finally, 
some reported a benefit of carrying the MTHFR 677T allele, but only for measures of 
processing speed (Araki et al., 2003; Durga et al., 2006). However the latter of these 
studies recruited only persons with elevated Hcy (> 13 µmol). Thus, the sample 
included a disproportionate number of T homozygotes compared to other samples, and 
could have been affected by an upwardly biased selection of survivors. 
Methodological Problems 
Both CRP and Hcy are readily assessed and widely available, and studies 
measuring these biomarkers and their correlates are proliferating. Although the 
literature supports the use of elevated CRP and Hcy blood levels as measures of 
cardiovascular risk, their use as markers of cognitive decline is less clear. While several 
studies have examined elevated blood levels of CRP or Hcy in relation to cognition, 
there is no consensus as to what specific domains are affected. Further, crude indices 
of cognitive function (e.g., MMSE) are frequently the only outcome measure assessed, 
contributing to the lack of specificity of the findings. Whereas several studies have 
shown an inverse association between elevations in CRP or Hcy and cognitive function, 
several others have not. Still, others have reported a positive correlation. The reason for 
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the disparity has largely been attributed to study design and the inclusion of multiple 
confounds.  
Among the prominent confounds are physiologic and lifestyle factors known to 
alter plasma levels of either CRP or Hcy. Although CRP is not susceptible to food intake 
and has little seasonal or diurnal variation, several characteristics of the metabolic 
syndrome (e.g., elevated blood pressure, elevated body mass index, diabetes mellitus, 
low high-density lipoprotein/high triglycerides), as well as cardiovascular risk factors 
associated with lifestyle (e.g., cigarette smoking), hormonal status as affected by 
estrogen/progesterone use, chronic infections (e.g., gingivitis, bronchitis), and systemic 
inflammatory conditions (e.g., rheumatoid arthritis, lupus, gout) are all known to 
increase CRP levels, whereas moderate alcohol consumption, increased 
activity/exercise, weight loss, and medication use (e.g., statins) and nutrition (e.g., 
fibrates, niacin) have all been shown to decrease CRP levels (Katrinchak & Fritz, 2007; 
Pearson et al, 2003). Several physiologic characteristics (e.g., older age, male sex), 
lifestyle determinants (e.g., protein intake, alcohol and caffeine consumption, smoking 
history) as well as various disease states (e.g., vitamin deficiency, renal failure, 
hypothyroidism, late-stage diabetes) have been associated with Hcy elevations, while 
vitamin intake and overactivity or minor aberrations in disease states (e.g., 
hyperthyroidism, early-stage diabetes) are associated with decreases in Hcy (Refsum et 
al., 2004). The literature to date is marred by a failure to recognize the impact of many 
of these factors, and when addressed, there is a general lack of adequate statistical 
control over their impact and an underreporting of effects by specific groups or 
stratifications (e.g., sex, ethnicity, supplement use, smoking status). 
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Neither physiologic or lifestyle factors act alone however, and there is an 
interplay among the various risk factors that leads to the development of high levels of 
CRP and Hcy, though the relative contribution of each is unknown (Kluijitmans et al., 
2003). Moreover, this interplay may be differentially associated with race, as various 
disease states occur more frequently among minority populations, diet is somewhat 
culturally regulated, and minor alleles are observed less frequently among minority 
populations (Albert et al., 2009), though population-specific effects are virtually 
unstudied at this juncture.  
Rationale and Hypotheses 
The reviewed literature suggests that elevated blood levels of CRP or Hcy may 
be independently associated with increased cardiovascular risk, poorer cognitive 
function, and increased risk for AD and VaD. However, efforts to examine the combined 
effects of CRP and Hcy elevations have been tenuous at best. Few studies (Fischer et 
al., 2006; Gunstad et al., 2006; Ravaglia et al., 2005; Silbert et al., 2008; van den 
Kommer et al., in press) have examined the combined impact of elevations in CRP and 
Hcy on cognition, and at present, only one study has demonstrated a relationship 
between genetic factors and biomarkers of inflammation. Namely, homozygosity for the 
T variant of the MTHFR 677C>T SNP was associated with higher baseline levels of 
both Hcy and CRP in seemingly healthy adults (Dedoussis et al., 2005). Perhaps most 
notable however, there has not been a study linking both genetic factors and the blood 
biomarkers of inflammation and cardiovascular disease under their regulatory control, to 
cognitive outcomes. To that end, the current study proposes to examine baseline blood 
levels of CRP and Hcy, and polymorphisms of the C>T>A -286 CRP and the 677C>T 
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MTHFR alleles, and their association with cognitive function across a variety of domains 
in a large and exceptionally healthy sample. In this way, many of the problems inherent 
to studies conducted thus far (e.g., small, heterogeneous sample selection) will be 
circumvented. Further, special care will be taken to rigorously control for other potential 
confounds on CRP and Hcy blood levels.  
Hypotheses 
1.) Elevations in blood levels of either CRP or Hcy will be associated with poorer 
cognitive performance.  Specifically, as elevations in both CRP and Hcy have 
been associated with an increased incidence of AD and VaD (Schmidt et al., 
2002), conditions with distinct cognitive impairments (Pantoni et al., 2009; 
Román, 2005; Solfrizzi et al. 2006), it is expected that declarative memory 
and executive functions domains will be most adversely affected. 
2.) Blood levels of CRP and Hcy will be moderately correlated. 
3.) The combined effect of elevated blood levels of CRP and Hcy on cognitive 
outcomes will be stronger than either CRP or Hcy alone. 
4.) Carriers of a T allele for either -286 C>T>A CRP or 677C>T MTHFR will 
experience higher blood levels of CRP and Hcy compared to the referent CC 
carriers. 
5.) Carriers of the T allele for either -286 C>T>A CRP or 677C>T MTHFR will 
exhibit poorer cognitive performance compared to the referent CC carriers, 
particularly for declarative memory and executive functions domains. 
6.) The combined effect of T allele of both -286 C>T>A CRP and 677C>T 
MTHFR on cognitive performance will be stronger than that of T allele status
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 for either -286 C>T>A CRP or 677C>T MTHFR alone particularly for      
declarative memory and executive functions domains. 
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CHAPTER 2 
METHOD 
Participants 
Participants were recruited from the community of a large Midwestern 
metropolitan area in the United States through posted flyers and media announcements 
as part of an ongoing five-year longitudinal study of healthy brain and cognitive aging. 
At baseline, a written questionnaire and telephone interview were used to exclude 
participants with a history of cardiovascular, neurological, endocrinological, metabolic, 
and psychiatric disease, head trauma associated with a loss of consciousness, drug or 
alcohol abuse, and uncorrected visual or hearing impairments. In addition, participants 
were screened for depression and dementia, using the Center for Epidemiologic 
Studies-Depression Scale (Radloff, 1977; cutoff = 16) and the Mini Mental State 
Examination (Folstein, Folstein, & McHugh, 1975; cutoff = 26/30) respectively. 
Participants who reported the use of glucose-lowering agents as well as centrally-acting 
medications such as anxiolytics, antidepressants, or anticonvulsants were also 
excluded. All participants were native English speakers, with a minimum of a high 
school education, right-hand dominant for basic manual activities (75% or greater on the 
Edinburgh Handedness Questionnaire; Oldfield, 1971), corrected visual acuity of 50/20 
or better (assessed by Optec 2000 apparatus, Stereo Optical Co. Inc., Chicago, IL), and 
hearing of 40 dB or better for frequencies of 500-4000 Hz (assessed by Maico, MA27 
audiometer, Maico Diagnostics, Eden Prairie, MN). All participants were given informed 
consent in compliance with Institutional Review Board and American Psychological 
Association requirements, and were monetarily compensated for their efforts.   
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Cognitive, blood marker, and genomic data were available for a total of 198 
participants (134 women). However, data from 9 participants (8 women) met criteria for 
an acute inflammatory condition (CRP > 10 mg/L), and data from 26 participants (13 
women) met criteria for hyperhomocysteinemia (Hcy > 12 µmol/L). Two participants 
(both women) met criteria for both an acute inflammatory condition and 
hyperhomocysteinemia. As values outside the normal reference range are indicative of 
inflammatory or subclinical cardiovascular processes, further analyses were restricted to 
participants whose CRP and Hcy values were within the reference range.  As is shown 
in Table 6, persons with values outside the reference range for either CRP or Hcy were 
on average older, had higher diastolic blood pressure, higher CRP and Hcy blood 
levels, and poorer MMSE performance than persons with values within the reference 
range limits. 
An additional 10 participants (three Hispanic, three Asian, two Indian, one 
Egyptian, and one Pacific Islander) were removed from analysis in order to conduct 
population analyses for the SNPs on a more homogenous genetic sample. These 
persons were on average younger and performed more poorly on the MMSE than 
persons retained for the final sample (Table 7).   
All told, the final sample was comprised of 151 persons (106 women). There 
were no differences between men and women in age, education, systolic or diastolic 
blood pressure, CRP levels, or MMSE performance, however men did have higher Hcy 
levels than women (t = 3.80, p = .001) in accord with the literature (Refsum et al., 2004). 
Descriptive statistics for the final sample by sex are reported in Table 8. 
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Table 6 
Comparison of Participants by Normal Reference Range CRP and Hcy Values 
Note. SD = standard deviation; t = student t-test value; p = significance; MMSE = Mini 
Mental State Exam  
 
Table 7 
Comparison of Participants by Population 
Note. CA = Caucasian American; AA = African American; SD = standard deviation; t = 
student t-test value; p = significance; MMSE = Mini Mental State Exam  
 Within Range (n = 161) Outside Range (n = 37)   
Variable Mean ± SD Mean ± SD t p 
Age  (years) 51.21 ± 14.81 57.65 ± 14.15 -2.41 < .02 
Education (years) 15.83 ± 2.54 15.92 ± 2.36 -.20 .84 
Systolic Blood Pressure (mmHg) 120.79 ± 13.24 124.98 ± 12.33 -1.76 .08 
Diastolic Blood Pressure (mmHg) 74.68 ± 7.99 77.84 ± 6.61 -2.24 < .03 
C-Reactive Protein (mg/L) 2.20 ± 2.22 8.03 ± 11.13 -6.16 < .001 
Homocysteine (µmol/L)   8.32 ± 1.71 13.05 ± 4.56 -10.37 < .001 
MMSE 28.92 ± 1.03 28.51 ± 1.24 2.08 < .04 
 CA/AA (n = 151) Other (n = 10)   
Variable Mean ± SD Mean ± SD t p 
Age  (years) 51.88 ± 14.53 41.00 ± 16.10 2.28 < .03 
Education (years) 15.75 ± 2.52 17.00 ± 2.79 -1.52 .13 
Systolic Blood Pressure (mmHg) 121.08 ± 13.40 116.47 ± 10.05 1.07 .29 
Diastolic Blood Pressure (mmHg) 74.75 ± 8.05 73.6 ± 7.28 .44 .66 
C-Reactive Protein (mg/L) 2.28 ± 2.26 1.08 ± 0.64 1.66 .10 
Homocysteine (µmol/L)   8.32 ± 1.70 8.31 ± 1.99 .02 .99 
MMSE 28.98 ± 0.98 28.00 ± 1.33 2.98 < .01 
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Table 8 
Sample Characteristics: Means, Standard Deviations and t-tests for Sex Differences 
Note. SD = standard deviation; t = student t-test value; p = significance; MMSE = Mini 
Mental State Exam  
 
Blood Biomarker Measurements 
 Following an overnight fast of 12 hours, participants reported to the clinic 
between 9 and 10 am, where venipuncture was done to obtain approximately 20 cc of 
whole blood for the analysis of plasma CRP, Hcy, and vitamins B6, B12, and folate. 
Samples for Hcy and vitamin B6 were placed in EDTA tubes, immediately placed on ice, 
and then centrifuged to separate plasma (within 30 minutes post-venipuncture). Vitamin 
B6 samples were additionally wrapped in paper to protect them from sunlight. The 
remaining samples were placed in serum separator tubes. With the exception of vitamin 
B6, all samples were processed in-house within four hours of venipuncture. Vitamin B6 
was shipped locally on dry ice for same day processing. CRP was determined by 
  Men (n = 45) Women (n = 106)   
Variable Range Mean ± SD Mean ± SD t p 
Age  (years) 18-77 52.84 ± 14.39 51.47 ± 14.64 .53 .60 
Education (years) 12-21 15.93 ± 2.81 15.67 ± 2.39 .59 .56 
Systolic Blood Pressure (mmHg) 91.33-156.67 123.61 ± 12.38 120.01 ± 13.73 1.52 .13 
Diastolic Blood Pressure (mmHg) 60.00-106.67 76.67 ± 8.51 73.93 ± 7.74 1.93 .06 
C-Reactive Protein (mg/L) 0.10-9.51 1.86 ± 1.57 2.45 ± 2.49 -1.48 .14 
Homocysteine (µmol/L)   3.70-11.80 9.10 ± 1.70 7.99 ± 1.59 3.80 .001 
MMSE 26-30 28.78 ± 1.00 29.01 ± 0.97 -1.66 .10 
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immunoturbidimetry, Hcy by fluorescence polarization immunoassay, vitamin B6 by 
radioenzymatic immunoassay, and vitamin B12 and folate by chemiluminescence. 
Genomic Analysis 
DNA was isolated from buccal cultures obtained in mouthwash. Isolation was 
performed using a Gentra Autopure LS (QIAGEN Inc., Valencia, CA) with the standard 
buccal cell protocol. For genotyping quality control, 10% direct repeats and DNA 
sequencing for verification were performed using both control DNA and no-template 
controls, whereby beta-globin was used as the amplification control. All 5’-nuclease 
assays were adapted from a quantitative PCR method (Lo et al., 2000) and 
implemented on an Applied Biosystems 7900. The CRP -286C>T>A polymorphism 
(rs3091244) utilized sense 5′-GAGGAGCAAGGAGAAGGAGTA-3′ and anti-sense 5′-
GGTCACGTCCTGCTGCCAGTGATA-3′ primers, and was amplified using a biotinylated 
antisense primer 5′-Bio-AGGGCTCCACTTTGGCTATC-3′. The MTHFR 677C>T 
polymorphism (rs1801133) was interrogated using the TaqMan SNP Genotyping Assay 
(Applied Biosystems, Foster City, CA) under the 0.5X protocol for ABI PRSIM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). Sequencing 
extension products were purified using Sephadex and the purified products were 
analyzed on an ABI PRISM 3700 DNA Analyzer using a 50 cm capillary array. 
 Almost 80% of the sample was evenly split among C homozygotes (39.1%, 59 
individuals) and C/T heterozygotes (39.7%, 60 individuals) for the CRP gene. The 
remaining 20% was approximately evenly split among T homozygotes (8.6%, 13 
persons), A/C heterozygotes (6.6% 10 persons), and A/T heterozygotes (6%, 9 
persons). There were no A homozygotes in the sample. The distribution of T 
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homozygotes conformed to the Hardy-Weinberg equilibrium: χ2 = 0.16, p = .70. With 
regards to the MTHFR allele, approximately half the sample was homozygous for the C 
allele (52%, 79 individuals), whereas 38% (57 individuals) were heterozygous, and a 
mere 10% (15 individuals) were homozygous for the T allele. The distribution of MTHFR 
C>T alleles did not deviate from Hardy-Weinberg equilibrium: χ2 = 0.86, p = .33. 
 There were both population and sex differences in the distribution of the various 
polymorphisms for the CRP gene, as can be seen in Figures 2 and 3 respectively. 
Similarly, the MTHFR gene was associated with differential distributions by both 
population (Figure 4) and sex (Figure 5), particularly for T homozygotes which were 
unrepresented among African Americans. 
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Figure 3 
 
CRP Gene Polymorphism Distribution by Sex 
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Figure 4 
 
MTHFR Gene Polymorphism Distribution by Population 
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Figure 5 
MTHFR Gene Polymorphism Distribution by Sex 
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Supplementary Questionnaire 
As participants for the current study had already completed the baseline 
assessment, an additional questionnaire was mailed to all participants to inquire about 
current and past dietary and nutrition supplements, alcohol and caffeine consumption, 
cigarette and other tobacco use, as well as anitlipidemic, anti-inflammatory, and 
estrogen use (Appendix A). Questionnaire responses were available on a subsample of 
94 participants (66 women). Survey respondents were on average older; had higher 
blood levels of Hcy, folate, vitamin B12, cholesterol, LDL, triglyceride, cholesterol ratio, 
and blood glucose; a higher diastolic blood pressure; and better MMSE performance 
than non-respondents. Only age and folate reached significance however (p > .05, all 
other’s ns). Conversely, non-respondents were better educated, had a higher systolic 
blood pressure, pulse pressure, and higher blood levels of CRP and HDL, though not 
significantly (all p’s > .18). There were fairly equal numbers of respondents and non-
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respondents across sex (70.21% vs. 70.18% for women and 29.79 vs. 29.83% for men), 
population (17.02% vs. 26.32% for African American, vs. 82.98% vs. 73.68% for 
Caucasian), and persons with a diagnosis of hypertension and/or characterized as 
hypertensive based on systolic and diastolic means (23.40% vs. 24.56%). 
Characteristics for survey respondents versus non-responders are reported in Table 9. 
Cognitive Tasks and Procedures 
Participants reported to the laboratory on three separate occasions for cognitive 
testing. At the start of each session, blood pressure was measured using a mercury 
sphygmomanometer (BMS 12-S25; Omron Healthcare, Bannockburn, IL) with a 
standard blood pressure cuff on the left arm with participants seated. The systolic and 
diastolic means were averaged for each participant and a mean systolic of 140 mmHg 
or a mean diastolic of 90 mmHg or more were classified as hypertensive. The cognitive 
tasks were administered to each participant individually in quiet, well-lit rooms with strict 
adherence to task and session order for all participants. For those tests requiring the 
administration of more than one block of trials, block order was counterbalanced across 
subjects. For tests requiring a delay within administration, every effort was made to 
maintain an equal period of delay across subjects. The cognitive tests were 
administered by extensively trained graduate and undergraduate students. 
Crystallized intelligence. Several subtests from the Educational Testing Service 
Referenced Factors Test Kit (Ekstrom, French, Harman, & Dermen, 1976a) were 
administered as a measure of crystallized intelligence. In these multiple-choice paper- 
pencil tests designed to test word knowledge, participants chose from 4 or 5 alternatives 
the synonym for the given word. Each of the five subtests has two parts, with a variable
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Table 9 
Sample Characteristics by Survey Response 
Note. SD = standard deviation; t = student t-test value, p = significance, LDL = low 
density lipoprotein; HDL = high-density lipoprotein; Cholesterol Ratio = Cholesterol/ 
HDL Cholesterol; MMSE = Mini Mental State Exam 
 
 
 
 Responders (n = 94) Non-responders (n = 57)   
Variable Mean ± SD Mean ± SD t p 
Age  (years) 54.03 ± 13.97 48.33 ± 14.86 2.37 < .05 
Education (years) 15.53 ± 2.46 16.11 ± 2.59 -1.36 .18 
Systolic Blood Pressure (mm Hg) 121.07 ± 13.29 121.10 ± 13.70 -.01 .99 
Diastolic Blood Pressure (mm Hg) 74.89 ± 7.22 74.52 ± 9.31 .28 .78 
Pulse Pressure (mm Hg) 46.18 ± 9.15 46.59 ± 9.02 -.27 .79 
C-Reactive Protein (mg/L) 2.27 ± 2.21 2.29 ± 2.37 -.05 .96 
Homocysteine (µmol/L)   8.39 ± 1.62 8.21 ± 1.83 .62 .54 
Folate (ng/mL) 19.04 ± 5.15 17.21 ± 4.93 2.15 < .05 
Vitamin B12  (pg/mL) 572.65 ± 238.49 569.46 ± 272.80 .08 .94 
Cholesterol (mg/dL) 202.16 ± 39.72 193.02 ± 38.55 1.39 .17 
LDL Cholesterol (mg/dL) 123.26 ± 34.06 114.19 ± 34.13 1.58 .12 
HDL Cholesterol (mg/dL) 55.62 ± 13.88 56.75 ± 15.82 -.46 .64 
Triglycerides (mg/dL) 116.54 ± 68.07 110.19 ± 66.68 .56 .58 
Cholesterol Ratio (mg/dL) 3.82 ± 1.11 3.63 ± 1.14 1.02 .31 
Blood Glucose (mg/dL) 88.46 ± 12.27 85.04 ± 10.69 1.71 .09 
MMSE 29.05 ± 0.96 28.86 ± 1.03 1.17 .24 
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number of items. For the current study, these have been modified from the standard test 
battery to eliminate words that have fallen out of usage or those that are not native to 
the English language.  The complete set of words was then randomly assigned across 
six comparable lists of 26 items each, so that each original list was equally represented 
across each of the newly derived lists.  Participants were given subtests one and two at 
baseline. The internal reliability for one of the subtests in its original form ranges from 
.81 to .89 (Ekstrom, French, Harman, & Dermen, 1976b). 
Fluid intelligence. Scale 3B of the Cattell-Culture-Fair Intelligence Test (Cattell 
& Cattell, 1960) was administered in its entirety as a measure of fluid intelligence. In this 
paper-pencil based task, participants view geometric designs and are asked to discover 
rules according to which the designs are arranged in series and matrices. In test one, 
participants are asked to find the drawing among six alternatives that would best 
complete the series. In test two, participants are instructed to find two drawings among 
five alternatives that are different in some way from the remaining choices. In the third 
part, participants are asked to identify which of six alternatives best completes the 
geometric matrix. Lastly, in part four, participants are given an abstract figure containing 
a dot and are asked to replicate the position of the dot among five alternatives. Internal 
consistency using Cronbach’s alpha has been estimated at .63, and construct validity at 
.81 for scale 3B (Cattell & Cattell, 1973).  
Declarative memory. Two declarative memory functions were assessed. 
Associative memory measured by the Memory for Names subtest from the Woodcock-
Johnson Psychoeducational Battery-Revised ([WJ-R], Woodcock & Johnson, 1989), 
and free recall by the Logical Memory subtest from the Wechsler Memory Scale-
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Revised ([WMS-R], Wechsler, 1987). In Memory for Names, participants are shown 
cartoons of “space creatures” and read aloud creatures “names” (nonsense one- or two-
syllable words). After presentation of name-picture pairs, participants are asked to point 
to the named space creature first alone, then among other space creatures. With each 
successive trial, participants are asked to learn the identity of a new space creature and 
retain the identity of all the preceding space creatures until all twelve are presented. 
Corrections are provided throughout acquisition. After a 20 min delay, participants are 
given three trials with no correction to identify the named space creature by pointing. 
The split-half reliability of the immediate and delayed recognition scores is .91 
(Woodcock & Mather, 1989).    
In Logical Memory, participants are read two short stories of just a few lines each 
and are asked to retell the story, verbatim. After a 20 min delay, participants are asked 
to repeat the stories. If they are unable to do so, a simple reminder cue is provided for 
one or both stories. The split-half reliability of this task is .74 for immediate and .75 for 
delayed presentation (Wechsler, 1987).  
Working memory. Participants performed two computerized versions of the 
nback task modeled after Dobbs and Rule (1989). In the verbal version, a series of 
digits (1-9) of variable length was presented. After the presentation, participants were 
asked to name the digit shown 1-, 2-, or 3-back in blocked trials of the same nback. 
Participants were aware of the condition being tested and were familiarized with each 
condition before the test trials. In the nonverbal version, a series of abstract drawings 
was presented, and at the end of each presentation, the participants were asked to 
indicate the drawing shown 1-, 2-, or 3-back. Trials were blocked and the participants 
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were aware of the condition prior to starting. For both versions, the indices of 
performance included both reaction time and number of errors. The test-retest reliability 
for the verbal version of the task is .68, .88, and .91, for 1-, 2-, and 3-back conditions 
respectively (Salthouse, Hancock, Meinz, & Hambrick, 1996).  
 Executive functions. Two executive functions were assessed: inhibition of pre-
potent response and perseveration. The response inhibition measures are in paper-and-
pencil format, whereas administration of the perseveration task is computerized.  
Two variants of a modified Stroop task (Stroop, 1935) modeled after Salthouse 
and Meinz (1995) were administered. In the color version, participants read aloud a 
page of words rendered in colors that are congruent or incongruent with the written 
word meaning, e.g., the word red printed in red ink (compatible) or in green ink 
(incompatible). In the position Stroop task, participants view a page of boxes bisected 
by either a horizontal or vertical line with a word printed in each box. The task is to 
identify the position of the word relative to the internal line. The position of the word is 
either consistent or inconsistent with its meaning, e.g., the word above could appear 
above (compatible) or below (incompatible) the line. Split-half reliability estimates of 
these tasks as a measure of interference are .72 for the color version and .70 for the 
position version (Salthouse & Meinz, 1995).   
 A computerized version of the Wisconsin Card Sorting Task (WCST: Computer 
Version 4 – Research Edition, Psychological Assessment Resources, Inc. Lutz, FL) was 
administered. Participants are to match the target card presented in the lower portion of 
the screen, to one of the four key cards presented at the top of the screen according to 
the color, shape, or number of geometric figures on the target card, using one of four 
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designated keys on the keyboard. Categories are presented in two repeated sets of 
blocks ordered as color, shape, number, with category switch occurring after 10 
successive correct trials. Participants are informed of their accuracy after each trial and 
continue until achieving all six categories, or after 128 trials. The total number of errors 
(incorrect matches), the number of perseverative errors (incorrect match according to 
current rule, but correct for the previous sorting rule), and the number of non-
perseverative errors (all other incorrect matches) were the indices of performance.  
Psychomotor speed. Psychomotor speed was assessed by two comparison 
tasks, both of which are modeled after Salthouse and Meinz (1995). In Letter 
Comparison, participants are presented with two columns of letter strings, three to nine 
letters each. Letter strings are either the same in both columns or differ by one letter. 
For each set of letter strings, participants are required to indicate whether the strings 
are the same or different. Pattern Comparison has two columns of abstract patterns that 
are either the same in both columns or with one line having a different orientation. For 
each set of abstract patterns, participants are required to indicate whether the patterns 
are the same or different. Participants are instructed to work as quickly and accurately 
as possible on each of two pages, with a time limit of 30 s per page. Test-retest 
reliability estimates for the Letter Comparison task have ranged from .77 to .80, and 
between .76 and .87 for Pattern Comparison (Salthouse et al., 1996; Salthouse & 
Meinz, 1995; Salthouse, Fristoe, McGuthry, & Hambrick, 1998).  
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CHAPTER 3 
RESULTS 
Data Conditioning and Analyses 
For the n-back tasks, trials resulting in errors were removed from analysis, as 
were trials in which reaction time was less than 500 ms or in excess of 10,000 ms, as 
these were deemed to reflect chance responding or motivational problems. The 
application of these criteria produced missing data for one block of trials in four cases 
(one verbal, three nonverbal). A computer malfunction resulted in three missing cases 
on the WCST task. In order to examine inhibition of the pre-potent response, the ratio of 
incompatible trials to neutral trials was examined separately for each Stroop task. 
Distributions for reaction time values on both versions of the n-back task, comparison 
tasks, and Stroop interference were skewed, as were distributions for error scores on 
both versions of the n-back and WCST, thus logarithmic transformation was applied to 
those variables. Scatterplots with blood level on the x-axis and cognition on the y-axis 
for the total sample and by SNP were analyzed for nonlinearity, as were 2-D mosaic 
surface plots with blood level on the x-axis, age on the y-axis, and cognition on the Z-
axis for both the total sample and by SNP. In all cases, there was little evidence for 
nonlinearity.  
Pearson product moment correlations were used to assess potential 
relationships among variables. In the full sample (n = 198), age and Hcy were 
significantly correlated (r = .32, p < .001), but CRP was unrelated to either age (r = .02, 
ns) or Hcy (r = -.02, ns). A similar pattern was found for the reduced sample (n = 151), 
such that age and Hcy were significantly correlated (r = .31, p <.001), but CRP was 
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unrelated to either age (r = .01, ns) or Hcy (r = .01, ns). Results were unchanged when 
Spearman’s rho for highly skewed variables was used (data not shown). Correlations 
among biological variables and cognitive indices in the final sample were similar to 
those of the full sample and are reported in Table 10.  
As the cognitive variables were moderately to highly correlated with one another 
on different measures of the same construct (r’s from .34 to .90), a factor analysis was 
conducted in order to create fewer, more parsimonious composite variables of similar 
constructs. Response time on the 3-back trials of the nback task was associated with 
considerable error (5.05 ± 3.60 for verbal; 9.45 ± 4.61 for nonverbal) and significant 
variability nearly double that of the easier trials (3728.23 ± 906.85 for 3-back, vs. 
2149.36 ± 459.49 for 1-back and 2566.59 ± 573.56 for 2-back), whereas accuracy on 
the 1- and 2-back nback trials resulted in near ceiling performance (0.32 ± 0.93 for 1-
back and 1.44 ± 2.14 for 2-back vs. 7.25 ± 3.53 for 3-back); therefore factor analysis 
was restricted to reaction time for 1- and 2-back trials, and errors for 3-back trials. 
The factor analysis with varimax rotation revealed five factors with eigenvalues 
greater than one. The first factor was predominantly categorized by measures of speed, 
and included both the 1- and 2-back trials from the verbal and nonverbal nback, as well 
as Letter and Pattern Comparison (factor loadings from .58 to .81). The second factor 
was predominantly a measure of general intelligence (‘g’) and inhibition, and included 
the CFIT, vocabulary, color and position Stroop interference, and WCST perseverative 
and nonperseverative errors (factor loadings from .43 to .82). The third factor 
constituted prose memory and included both the immediate and delayed administrations 
of Logical Memory (factor loadings of. 91). The fourth factor was associative memory
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Table 10  
Correlation Matrix of Biological and Cognitive Study Variables 
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and included both the immediate and delayed administrations of the Memory for Names 
task (factor loadings of .78 and .82). Lastly, the fifth factor was an accuracy factor and 
comprised errors from both versions of the nback (factor loadings of .64 and .83). 
Results from the factor analysis are summarized in Table 11. 
The General Linear Model (GLM) approach was used to assess the relationship 
between age, sex, hypertension status (diagnosis or mean systolic ≥ 140 mmHg and/or 
mean diastolic ≥ 90 mmHg), blood biomarkers, and cognitive functions. In such 
analyses, the respective cognitive function(s) served as the dependent variable, 
whereas age, CRP, and Hcy were centered at their sample means and entered as 
continuous independent variables. Sex and hypertension status were categorical 
independent variables.  
In a separate set of GLM analyses assessing the relationship between SNPs and 
cognitive function, allele status (three levels for CRP -286 C>T>A and two levels for 
MTHFR 677C>T), hypertension status, and sex were entered as categorical variables, 
and age, CRP, and Hcy were centered to the mean and entered as continuous 
independent variables; whereas cognitive function was entered as the dependent 
variable. Given the small number of participants homozygous for the T allele in either 
SNP (13 for CRP, and  15  for  MTHFR),  carriers  homozygous  for  the  T  allele  were  
grouped  with heterozygote carriers. Similarly, there were no homozygous carriers for 
the A allele for the CRP SNP, therefore, A carriers comprised A/C and A/T 
heterozygotes. 
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Table 11 
Factor Loadings for Exploratory Factor Analysis with Varimax Rotation of Cognitive 
Variables  
Variable Speed ‘g’/Inhibition Prose Association Accuracy 
NbV1rt      .81 .26 .07 .04 -.05 
NbV2rt .71 .32 .07 -.04 -.13 
NbNV1rt .80 .12 .09 -.29 .03 
NbNV2rt .79 .11 .20 -.23 -.01 
LetComp -.58 .07 -.21 .42 .37 
PatComp -.59 -.02 -.19 .29 .37 
CFIT -.28 -.52 -.28 .30 .29 
Vocab .33 -.43 -.23 .25 .24 
Cinterfer .42 .51 .02 -.45 -.11 
Pinterfer .12 .54 .06 -.56 .17 
WCSTPE .26 .82 .13 -.15 -.19 
WCSTNPE .21 .78 .16 -.04 -.24 
LM -.20 -.16 -.91 .14 .10 
LMD -.16 -.20 -.91 .20 .11 
Names -.21 -.15 -.21 .82 .24 
NamesD -.21 -.19 -.21 .78 .30 
NbV3er .02 .17 .09 -.17 -.83 
NbNV3er .18 .36 .09 -.12 -.64 
Note. Parsimonious factor loadings are in boldface.  NbV1rt & NbV2rt = Nback Verbal 1- 
and 2-back reaction time; NbNV1rt & NbNV2rt = Nback Nonverbal 1- and 2-back 
reaction time; LetComp & PatComp = Letter and Pattern Comparison; CFIT = Culture 
Fair Intelligence Test Scale 3B; Vocab = Educational Testing Services Vocabulary Test; 
Cinterfer & Pinterfer = Color and Position Stroop Interference; WCSTPE & WCSTNPE = 
Wisconsin Card Sorting Task perseverative and nonperseverative errors; LM & LMD = 
Logical Memory immediate and delayed administrations; Names & NamesD = Memory 
for Names immediate and delayed administrations; NbV3er = Nback Verbal 3-back 
errors; NbNV3er = Nback Nonverbal 3-back errors. 
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For each analysis, a full model that included all second-order interactions was 
tested first. All interactions that did not reach statistical significance (p < .10) were 
removed from analyses, and the analyses repeated without their inclusion. Reduced 
models of the GLM analyses were followed by univariate analyses of simple effects, and 
testing the differences among the levels of categorical variables with Fisher’s Least 
Significant Difference (LSD) test, or slope of regression on the continuous variables by 
comparing the 95% confidence intervals around them. 
Pair-wise comparisons on the use/abstinence of various medications/activities 
(e.g., hormone replacement therapy, dietary supplements, statins, anti-inflammatories, 
exercise, alcohol, caffeine) and presence/absence of various conditions (e.g., arthritis, 
high-cholesterol, impaired fasting glucose, infections) known to affect CRP and Hcy 
levels were also conducted on a subsample of participants with completed 
supplementary questionnaire data. 
Hypothesis 1: Elevations in CRP or Hcy will be associated with poorer cognition 
 In order to test whether elevated blood levels of CRP or Hcy were related to 
cognitive performance, a series of 10 GLM (five for each blood biomarker) analyses 
were conducted with each of the five factors entered as continuous dependent variables 
in turn. With the exception of prose and associative memory, the other factors were 
highly skewed and were therefore log transformed before entry into the GLM. In each 
GLM, age and the blood biomarker (either CRP or Hcy) were centered to the mean and 
entered as continuous independent variables, whereas sex and hypertension status 
were categorical independent predictors. 
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Psychomotor speed. The composite score of psychomotor speed was derived 
by averaging performance on both versions of the nback for 1- and 2-back trials, as well 
as the number of items correctly completed on each of the comparison tasks. The 
composite score was then entered as the continuous dependent variable in each of two 
separate GLM analyses. In each of the GLMs, results indicated a significant main effect 
of age attributed to slower performance with increasing age (β = .39, p < .001). The 
GLM with CRP as an independent variable additionally revealed a significant main 
effect of hypertension status attributed to slower performance among hypertensives 
(Fisher’s LSD p = .04).  No other significant main effects or interactions were found. 
Significant effects for CRP are summarized in Table 12, and for Hcy in Table 13.  
Examination of n-back RT and comparison task performance separately resulted 
in additional effects. Namely, all models revealed significant main effects of age, as well 
as a significant interaction of Sex × Hypertension status, reflective of slower 
performance and fewer comparisons among female hypertensives. Additionally, the 
analysis conducted on n-back RT with CRP alone revealed a significant main effect of 
hypertension, whereas the analysis on the comparison tasks with Hcy alone resulted in 
a significant main effect of Hcy reflective of fewer comparisons with higher Hcy levels 
(data not shown). 
‘g’ and inhibition. A composite score of ‘g’/inhibition was derived by averaging 
performance from the CFIT, vocabulary, each of two measures of Stroop interference, 
and perseverative and non-perseverative errors from the WCST. First, a summary 
variable was created for each of the cognitive variables included in the composite. 
Performance on scale 3B of the Cattell Culture Fair Intelligence Test was created by  
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Table 12  
General Linear Model Analysis: Summary of Significant Effects and Trends of CRP 
Singularly 
  
Task Effect df F p 
Psychomotor Speed Age 1, 144 19.94 < .001 
 Hypertension 1, 144 4.32 < .05 
‘g’/Inhibition Age 1, 139 36.57 < .001 
Prose Memory Age 1, 145 6.89 = .01 
 CRP 1, 145 3.69 < .06 
 CRP × Sex 1, 145 3.05 < .09 
Associative Memory Age 1, 146 24.57 < .001 
Accuracy Age 1, 145 12.19 = .001 
Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance level; 
‘g’ = general intelligence; CRP = C-reactive protein 
 
 
Table 13 
General Linear Model Analysis: Summary of Significant Effects and Trends of Hcy 
Singularly 
 
Task Effect df F p 
Psychomotor Speed Age 1, 142 17.85 < .001 
‘g’/Inhibition Age 1, 137 35.72 < .001 
Prose Memory Age 1, 144 9.20 < .01 
 Hcy 1, 144 3.46 < .07 
Associative Memory Age 1, 144 24.98 < .001 
Accuracy Age 1, 143 14.88 < .001 
Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance level; 
‘g’ = general intelligence; Hcy = homocysteine 
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summing all items answered correctly under the untimed administration in each of the 
four subtests. For vocabulary, a composite score was derived by summing the total 
number of items answered correctly and multiplying this by a fraction (0.25) of the total 
number of items answered incorrectly on each of the two subtests during the untimed 
administration. Interference on the Stroop task was first computed as the ratio of 
response time on the average of the incompatible trials to the average of response time 
on the neutral trials for each task. The composite variable of all measures combined 
was then entered as the continuous dependent variable in the GLM. Both GLMs 
revealed only a significant main effect of age attributed to greater ‘g’ with increasing age 
(β = .46, p < .001). No other significant main effects or interactions were found. 
Significant effects for CRP are summarized in Table 12, and Hcy in Table 13. 
 When the results were analyzed separately for each of the tests within the factor, 
all models yielded significant effects of age, and most revealed effects or trends of sex, 
and Age × Sex interactions. For the analysis conducted on Vocabulary in CRP alone, 
there was a main effect of CRP, such that higher levels were associated with reduced 
performance (data not shown). 
Prose memory. A composite for prose memory was derived by averaging 
performance on the Logical Memory task for the immediate and delayed 
administrations, and then entered as a continuous dependent variable in the GLM. Both 
analyses indicated a significant main effect of age reflective of poorer performance 
among older persons (β = -.22, p < .01). Additionally, in the GLM conducted on CRP as 
an independent predictor, the main effect of CRP approached significance [F(1, 145) = 
3.69, p = .057] as did the CRP × Sex interaction [F(1, 145) = 3.05, p = .083], reflective  
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of poorer performance with higher blood levels of CRP (β = -.08, ns), particularly among 
men (β = -.29, p = .05 vs. β = -.03, ns; Figure 6). Conversely, the GLM conducted on 
Hcy identified a main effect of Hcy that approached significance [F(1, 144) = 3.46, p = 
.065] reflective of better performance with higher blood levels of Hcy (β = .06, ns). 
Results from the GLM conducted on CRP are summarized in Table 12, and for Hcy in 
Table 13. 
 
Figure 6 
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Associative memory. The composite for associative memory was derived by 
averaging performance from the Memory for Names immediate and delayed 
administrations then entered as the continuous dependent variable in the GLM. The 
analysis revealed only a significant main effect of age reflective of poorer performance 
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with older age (β = -.41, p <.001). These results are summarized in Tables 12 (CRP) 
and 13 (Hcy). 
Accuracy. The composite for accuracy was derived by averaging the number of 
errors made on the 3-back condition for each version of the nback and then entered as 
the continuous dependent variable in the GLM. Results indicated only a significant main 
effect of age, reflective of more errors made with older age (β = .31, p <.001). These 
results are summarized in Tables 12 (CRP) and 13 (Hcy). 
Hypothesis 2: Blood levels of CRP and Hcy will be moderately correlated 
In both the full sample (n = 198) and the reduced sample (n = 151), CRP and 
Hcy were unrelated with one another (r = -.02 and r = -.01 respectively).  Although 
restriction of analysis to CRP values above the reference range (≥ 10 mg/L, n = 11) 
resulted in a strengthening of the association (r = .20), as did restriction of analysis to 
values outside the reference range for Hcy (≥ 12 µmol/L, n = 27; r = -.12), neither was 
significant. Only when the analysis was restricted to those cases above the reference 
range for either CRP or Hcy (n = 36) was there a significant correlation between the two 
(r = -.48, p < .01). There was an insufficient number of cases (n = 2) to analyze persons 
with elevations in both. 
Hypothesis 3: The combined effect of elevated blood levels of CRP and Hcy on 
cognitive outcomes will be stronger than either CRP or Hcy alone. 
 In order to test whether the combined effects of elevated blood levels of CRP and 
Hcy on cognition were stronger than either effect alone, the GLM analyses were 
repeated with both CRP and Hcy centered to the mean and entered as continuous 
independent variables.  
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Psychomotor speed. Results indicated a significant main effect of age attributed 
to slower performance with increasing age (β = .39, p < .001). Although there was not a 
main effect of Hcy within the GLM, there was a significant Age × Hcy interaction, 
reflective of a slowing of response time with higher Hcy levels, but only among the most 
aged. Age most likely was functioning as a suppressor variable, as the inclusion of Hcy 
in the regression analysis explained additional variance over age alone (β = .39 vs. β = 
.388). The CRP × Hcy interaction approached significance, F(1, 139) = 3.76, p < .06, 
and reflected the fact that CRP and Hcy had slopes in the opposite direction of one 
another (β = -.06, ns vs. β = .16, p <.05). These interactions are shown in Figure 7, and 
results for the combined analysis are summarized in Table 14. 
Analysis of n-back RT and comparison task performance separately resulted in 
the same age effects, as well as significant interactions of Sex × Hypertension status, 
and a significant main effect of Hcy on comparison task performance as in the analyses 
conducted on CRP and Hcy separately. Moreover, the CRP × Hcy interaction reached 
significance in the analysis conducted on n-back RT alone, as did the Hcy × Sex 
interaction (data not shown). 
‘g’ and inhibition. The GLM on the ‘g’/Inhibition factor revealed only a significant 
main effect of age attributed to greater ‘g’ with increasing age (β = .46, p < .001). No 
other significant main effects or interactions were found. Results are summarized in 
Table 14. 
Interestingly, when the analyses were repeated on each of the tests comprising 
the ‘g’/inhibition factor alone, many of the same effects emerged as when CRP and Hcy 
were analyzed separately. Namely, the analysis on the CFIT revealed a significant main  
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Figure 7  
Age and C-Reactive Protein on Speed as a Function of Homocysteine Levels 
 
 
 
 
Table 14 
General Linear Model Analysis: Summary of Combined Significant Effects and Trends 
 
Task Effect df F p 
Psychomotor Speed Age 1, 139 22.57 < .001 
 Age × Hcy 1, 139 5.04 < .05 
 CRP × Hcy 1, 139 3.76 < .06 
‘g’/Inhibition Age 1, 135 37.26 < .001 
Prose Memory Age 1, 142 10.38 < .01 
 Hcy 1, 142 7.42 < .01 
 Hcy × Sex 1, 142 7.24 < .01 
Associative Memory Age 1, 143 34.54 < .001 
Accuracy Age 1, 142 14.74 < .001 
Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance level; 
‘g’ = general intelligence; CRP = C-reactive protein; Hcy = homocysteine 
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effect of sex, and the analysis on the Stroop revealed a significant Sex × Age 
interaction.  Additionally, the analysis conducted on Vocabulary revealed a significant 
CRP × Hcy interaction, reflective of the fact that CRP and Hcy had slopes in the 
opposite direction of one another (data not shown). 
Prose memory. The GLM on prose memory indicated a significant main effect of 
age reflective of poorer performance among older persons (β = -.22, p <.01). Although 
the main effect of Hcy was significant [F(1, 142) = 7.42, p < .01], the post-hoc 
regression analysis was not (β = .06, ns), thus indicating a suppressor effect of age on 
Hcy. As is shown in Figure 8, the significant Hcy × Sex interaction indicated higher 
blood levels of Hcy were associated with more items recalled in men (β = .28, p <.07), 
but not women (β = -.07, ns). Results from the GLM are summarized in Table 14. 
Associative memory. As with the analyses conducted on CRP or Hcy singularly 
and shown in Table 14, the combined analysis revealed only a significant main effect of 
age reflective of poorer performance among older persons (β = -.41, p <.001). 
Accuracy. Similarly, results on the combined GLM for accuracy revealed only a 
significant main effect of age, reflective of more errors made with older age (β = .31, p 
<.001; Table 14). 
Hypothesis 4: Carriers of the T allele for either -286 C>T>A CRP or 677C>T 
MTHFR will experience higher blood levels of CRP and Hcy compared to the 
referent CC carriers. 
In order to test whether blood levels were higher among carriers of the T allele, a 
series of two-sample t-tests were conducted where carrier status was the grouping 
variable, and blood levels of either CRP or Hcy the dependent variable. Blood levels  
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Figure 8 
Prose Recall and Homocysteine by Sex 
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were not significantly different among carriers of the T allele for either CRP (t = .74, ns) 
or Hcy (t = -1.22, ns) compared to the referent homozygous C carriers. However, 
carriers of the A allele had significantly higher blood levels of CRP than C homozygotes 
(t = 2.01, p < .05). Moreover, when blood levels were evaluated by T allele 
homozygosity, T homozygotes had CRP blood levels intermediary between CC and C/T 
carriers at the low end, and A/C and A/T carriers at the high end (Figure 9). Hcy levels 
among T homozygotes were the lowest relative to either C/T or C/C carriers (Figure 10). 
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Figure 9 
C-Reactive Protein Blood Level by CRP Polymorphism 
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Figure 10 
Homocysteine Blood Level by MTHFR Polymorphism 
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Hypothesis 5: Carriers of the T allele for either -286 C>T>A CRP or 677C>T 
MTHFR will exhibit poorer cognitive performance compared to the referent CC 
carriers.  
To test T allele effects on cognition, GLM analyses were repeated with age and 
the respective blood biomarker centered to the mean and entered as continuous 
independent variables, and allele, sex, population (Caucasian/African American), and 
hypertension entered as categorical independent variables on separate GLM analyses 
for each of the five dependent cognitive factors. 
Psychomotor speed. Both the GLM analysis on CRP and MTHFR revealed 
significant main effects of age reflective of slower response times among older persons 
(β = .39, p < .001). The GLM on CRP identified additional main effects of population and 
CRP polymorphism, reflective of slower response times among African Americans 
(Fisher’s LSD p < .001) and carriers of the T allele relative to either the A (Fisher’s LSD 
p = .003) or C (Fisher’s LSD p = .004) alleles. Results from the GLM for CRP are 
summarized in Table 15, and for MTHFR in Table 16. 
When n-back RT and comparison task performance were analyzed separately, 
the same age and population effects emerged, but the CRP main effect was no longer 
significant. Instead, the analysis conducted on n-back RT alone revealed a main effect 
of hypertension status and a significant Sex × Hypertension status interaction for both 
models. Similarly, the analysis conducted on the comparison tasks alone revealed 
significant interactions of Sex × Hypertension status and Race × Gene polymorphism. 
There was also a main effect of Hcy in the analysis conducted on Hcy alone (data not 
shown). 
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Table 15 
General Linear Model Analysis: Summary of Significant Effects and Trends of CRP 
Gene 
 
Task Effect df F p 
Psychomotor Speed Age 1, 141 21.74 < .001 
 
CRP 2, 141 5.02 < .01 
 Population 1, 141 15.01 < .001 
‘g’/Inhibition Age 1, 132 53.85 < .001 
 CRP 1, 132 3.24 < .08 
 Population 1, 132 21.11 < .001 
 Age × Sex 1, 132 4.23 < .05 
 
CRP × Sex 2, 132 4.37 < .05 
Prose Memory Age 1, 141 3.94 < .05 
 Age × Sex 1, 141 6.36 < .05 
 Hypertension × Population 1, 141 6.12 < .05 
Associative Memory Age 1, 143 26.47 < .001 
 Population 1, 143 5.86 < .05 
Accuracy Age 1, 142 14.75 < .001 
 Population 1, 142 9.09 < .01 
Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance level; 
‘g’ = general intelligence; CRP = -286 C>T>A CRP gene 
 
 ‘g’ and inhibition. Each of the GLM’s conducted on CRP and MTHFR revealed 
significant main effects of age and population reflective of better ‘g’ performance among 
older persons (β = .47, p <.001) and Caucasians (Fisher’s LSD p < .001). Although not 
significant, there was a trend for a main effect of CRP in the GLM conducted on CRP: 
F(1, 132) = 3.24, p < .08. Also in this GLM and as shown in Figure 11, the age effect 
was additionally modified by a significant Age × Sex interaction, which showed greater 
‘g’ performance among men with older age (β = .59, p <.001 vs. β = .42, p < .001). As is 
shown in Figure 12, a significant CRP × Sex interaction indicated better performance  
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Table 16 
General Linear Model Analysis: Summary of Significant Effects and Trends of MTHFR 
Gene 
  
Task Effect df F p 
Psychomotor Speed Age 1, 138 24.48 < .001 
‘g’/Inhibition Age 1, 132 49.11 < .001 
 Population 1, 132 25.45 < .001 
Prose Memory Hcy 1, 138 8.83 < .01 
 Hypertension 1, 138 4.04 < .05 
 Population 1, 138 12.17 = .001 
 
Age × MTHFR 1, 138 5.08 < .05 
 Age × Hypertension 1, 138 7.01 < .01 
 Hcy × Sex  1, 138 10.13 < .01 
 
MTHFR × Hypertension 1, 138 5.91 < .05 
Associative Memory Age 1, 142 27.13 < .001 
 Population 1, 142 5.18 < .05 
Accuracy Age 1, 141 18.19 < .001 
 Hcy 1, 141 4.43 < .05 
 Population 1, 141 11.51 = .001 
 Sex 1, 141 4.14 < .05 
Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance level; 
‘g’ = general intelligence; Hcy = homocysteine; MTHFR = 677C>T MTHFR gene 
 
among men compared to women with the A allele (Fisher’s LSD p = .046), and better 
performance among women compared to men with the T allele (Fisher’s LSD p = .029).  
Additionally, men with the A allele performed better compared to women homozygous 
for the C allele (Fisher’s LSD p = .013). Within sex differences were also noted, namely 
among women, performance was better among carriers of the T allele compared to C 
homozygotes (Fisher’s LSD p =.021); and among males, performance was better 
among carriers of the A allele relative to either carriers of the T allele (Fisher’s LSD p = 
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.012) or C homozygotes (Fisher’s LSD p = .04). Results from the GLM on CRP are 
summarized in Table 15, and on MTHFR in Table 16. 
When the analyses were repeated with the individual tests separately, analyses 
conducted on Hcy alone revealed only significant main effects of age and population. 
For those conducted on CRP however, several significant interactions with age were 
revealed such that fluid intelligence was higher among T carriers relative to A carriers, 
and males had more interference on the Stroop. A significant Sex × Gene polymorphism 
interaction on the WCST revealed fewer perseverative errors among female C carriers 
than female T carriers, but more errors among male A carriers than male T carriers 
(data not shown). 
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Figure 12 
‘g’ by CRP Polymorphism and Sex 
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Prose memory. The GLM analysis conducted on CRP identified a significant 
main effect of age which was modified by a significant interaction of Age × Sex. Older 
persons recalled fewer items (β = -.22, p < .01), particularly women (β = -.32, p = .001 
vs. β = .03, ns; Figure 13).  As shown in Figure 14, the Hypertension × Population 
interaction reflected the fact that African American persons without hypertension 
recalled fewer items than African Americans with hypertension (Fisher’s LSD p = .03), 
Caucasians without hypertension (Fisher’s LSD p < .001), or Caucasians with 
hypertension (Fisher’s LSD p = .018). GLM results are summarized in Table 15. 
 Conversely, in the GLM conducted on MTHFR, the main effect of age was not 
significant (F < 1), however, significant main effects of hypertension and population 
were found, reflective of fewer items recalled among hypertensives (Fisher’s LSD p = 
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.046) and African American’s (Fisher’s LSD p = .001) as summarized in Table 16. As 
with the analysis conducted on CRP and Hcy blood levels on cognition, the main effect 
of Hcy was significant in the absence of a significant effect on post-hoc regression 
analysis (β = .06, ns). However, as the standardized coefficient was in the opposite 
direction to that of the one for age (β = -.22) and added additional variance to that of 
age alone (β = -.26), it is likely age was acting as a suppressor variable. Several 
significant interactions modified the main effects for the GLM on MTHFR. The Age × 
MTHFR reflected the fact that with older age, C homozygotes performed more poorly 
than T carriers (β = -.29, p < .01 vs. β = -.11, ns; Figure 15). As shown in Figure 16 and 
demonstrated by the significant Age × Hypertension interaction, prose recall was poorer 
among older normotensives (β = -.24, p = .01 vs. β = -.05, ns). A significant interaction  
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Figure 14 
Prose Recall by Population and Hypertension Status 
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Prose Recall and Age by MTHFR Polymorphism 
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Figure 16 
 
Prose Recall and Age by Hypertension Status 
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of Hcy × Sex showed men with higher Hcy levels recalled more items than women (β = 
.28, p < .07 vs. β = -.07, ns; Figure 8). Lastly, a significant interaction of MTHFR × 
Hypertension revealed hypertensives with T carriage recalled fewer items than 
normotensives with T carriage (Fisher’s LSD p = .006; Figure 17). Results for the GLM 
conducted on MTHFR are summarized in Table 16. 
Associative memory. The GLM analyses for both CRP and MTHFR on 
associative memory revealed only significant main effects of age and population, 
reflective of fewer associations made by older persons (β = -.41, p < .001) and African 
Americans (Fisher’s LSD p = .017) as shown in Table 15 (CRP) and Table 16 (MTHFR).  
Accuracy. Similarly, the GLM on accuracy revealed significant main effects of 
age and population, reflective of more errors made with older age (β = .31, p <.001) and 
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Figure 17 
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among African Americans (Fisher’s LSD p = .003) as shown in Table 15 (CRP) and 
Table 16 (MTHFR). The GLM on MTHFR revealed a main effect of sex, reflective of 
more errors made by men (Fisher’s LSD p = .044). The significant main effect of Hcy in 
the absence of a significant post-hoc regression most likely is indicative of a suppressor 
effect of age on Hcy given the additional variance explained with the inclusion of Hcy 
over age alone (β = .32 vs. β = .31). 
Hypothesis 6: The combined effect of T allele of both -286 C>T>A CRP and 
677C>T MTHFR on cognitive performance will be stronger than that of T allele 
status for either -286 C>T>A CRP or 677C>T MTHFR alone. 
 In order to test the combined effect of CRP and MTHFR T carrier status on 
cognitive function, the GLMs were repeated with age, CRP, and Hcy centered to the 
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mean and entered as continuous independent variables; and sex, hypertension, 
population, and allele status (three levels for CRP and two levels for MTHFR) entered 
as categorical independent variables. Each of the cognitive factors was entered in turn 
as the dependent variable. 
Psychomotor speed. Similar to the GLM conducted on CRP alone, the GLM on 
the combined analysis of CRP and MTHFR revealed significant main effects of age, 
CRP, and population, reflective of faster response times among younger persons (β = 
.39, p < .001), carriers of the A allele relative to either the T (Fisher’s LSD p = .007) or C 
alleles (Fisher’s LSD p = .007), and Caucasians (Fisher’s LSD p = .008). Although not 
significant, the interaction of CRP × Hcy approached significance, F(1, 135) = 3.74, p = 
.055, and reflected the fact that CRP and Hcy were inversely related to processing 
speed (β = -.07, ns for CRP vs. β = .16, p <.05 for Hcy). Results for the combined GLM 
are summarized in Table 17. 
Similarly, the results on n-back RT and Comparison analyzed separately 
revealed significant age and population effects for both models, as well as a significant 
main effect of CRP for the n-back RT task. The CRP × Hcy reached significance in both 
models, reflective of the fact that CRP and Hcy were inversely related with cognition. 
Several additional effects and interactions were noted for the analysis conducted on n-
back RT, namely, significant interactions of Hcy × Age, Hypertension status × Age, and 
CRP gene × Hcy (data not shown). 
‘g’ and inhibition. The GLM for ‘g’/inhibition revealed significant main effects of 
age and population indicative of better ‘g’ performance among older persons (β = .47, p 
< .001) and among Caucasians (Fisher’s LSD p <.001). Though not significant, the main 
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Table 17 
General Linear Model Analysis: Summary of Significant Effects and Trends of both 
SNPs 
 
Task Effect df F p 
Psychomotor Speed Age 1, 135 24.95 < .001 
 
CRP 2, 135 4.17 < .05 
 Population 1, 135 7.18 < .01 
 CRP × Hcy 1, 135 3.74 < .06 
‘g’/Inhibition Age 1, 129 47.13 < .001 
 CRP 1, 129 3.54 < .07 
 Population 1, 129 18.85 < .001 
 
CRP × Sex 2, 129 3.17 < .05 
Prose Memory Age 1, 136 9.41 < .01 
 Hcy 1, 136 6.69 < .05 
 Population 1, 136 8.36 < .01 
 
Age × MTHFR 1, 136 3.28 < .08 
 
Hcy × MTHFR 1, 136 3.02 < .09 
 Hcy × Sex  1, 136 6.87 = .01 
Associative Memory Age 1, 139 26.35 < .001 
 Population 1, 139 4.62 < .05 
Accuracy Age 1, 132 19.57 < .001 
 Hcy 1, 132 6.48 < .05 
 Population 1, 132 10.07 < .01 
 Sex 1, 132 2.97 < .09 
 
Age × CRP 2, 132 2.36 < .10 
 CRP × Sex 1, 132 3.35 < .07 
 
CRP × MTHFR 2, 132 2.78 < .07 
Note. Note. df = degrees of freedom; F = F statistic derived from GLM; p = significance 
level; ‘g’ = general intelligence; CRP = C-reactive protein; Hcy = homocysteine; CRP = -
286 C>T>A CRP gene; MTHFR = MTHFR = 677C>T MTHFR gene 
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effect of CRP approached significance, F(1, 129) = 3.54, p < .07,  indicative of a trend 
towards poorer ‘g’ performance with higher CRP levels (β = -.11, ns). As shown in 
Figure 12, the CRP × Sex interaction indicated better performance among T carriers in 
women relative to women C homozygotes (Fisher’s LSD p = .035), and among A 
carriers in men relative to either C homozygotes in women (Fisher’s LSD p = .03), or T 
carriers in men (Fisher’s LSD p =.034). Results are summarized in Table 17. 
An analysis conducted on each of the tasks separately revealed the same 
significant main effects of age and population, and a CRP × Sex interaction which was 
only significant for the model conducted on Stroop. Additional interactions of CRP gene 
polymorphism were found such that older age was associated with reduced fluid 
intelligence in C carriers, T carriage with higher Hcy levels was associated with better 
vocabulary performance, and females homozygous for the C allele made fewer 
perseverative responses than females with the T allele. 
Prose memory. The GLM conducted on prose memory revealed significant main 
effects of age and population indicative of fewer items recalled among older age (β = -
.22, p < .01), and among African Americans (Fisher’s LSD p = .004). As with the GLM 
conducted on Hcy alone, the main effect of Hcy was significant [F(1, 136) = 6.69, p < 
.05] in the absence of a significant beta on post-hoc regression (β = .06, ns), thus 
indicating a suppressor effect of age on Hcy. The significant Hcy × Sex interaction 
indicated lower blood levels of Hcy were associated with more items recalled in men (β 
= .28, p <.07), but not women (β = -.07, ns; Figure 8). Neither the Age × MTHFR nor the 
Hcy × MTHFR interactions were significant, but there was a trend for worse 
performance among C homozygotes than T carriers with age (β = -.29, p < .01 vs. β = -
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.11, ns; Figure 15); and worse among T carriers versus C homozygotes with higher Hcy 
levels (β = .18, ns vs. β = -.05, ns; Figure 18). Results for the GLM are summarized in 
Table 17. 
 
Figure 18 
 
Prose Recall and Homocysteine by MTHFR Polymorphism 
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Associative memory. The GLM on associative memory identified only 
significant main effects of age and population, again reflecting fewer associations 
among older persons (β = -.41, p < .001) and African Americans (Fisher’s LSD p =.033). 
These results are summarized in Table 17. 
Accuracy. The GLM on accuracy revealed significant main effects of age and 
population, reflective of more errors in older persons (β = .31, p < .001) and among 
African Americans (Fisher’s LSD p = .002). As with previous analyses, the main effect of 
Hcy was significant in the absence of a significant beta on post-hoc regression (β = .01, 
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ns) with an additive contribution to the total variance explained over age alone (β = .33 
vs. β = .31). Both the main effect of sex and the CRP × Sex interaction approached 
significance as males tended to make more errors than females (Fisher’s LSD p = .072), 
but in the presence of higher CRP blood levels, the opposite was true (β = -.10, ns for 
men vs. β = .11, ns for women; Figure 19). The CRP × MTHFR interaction also 
approached significance namely due to the fact that carriers of the A allele for CRP and 
the T allele for MTHFR, made more errors than either C (Fisher’s LSD p = .028) or T 
carriers of CRP (Fisher’s LSD p = .016) who were T carriers for the MTHFR allele 
(Figure 20). Lastly, the non-significant interaction of Age × CRP indicated that although 
there was a linear increase in the number of errors made across all polymorphisms, the 
slope was less steep among T carriers in older age (β = .22, ns vs. β = .43, ns in A 
carriers, and β = .40, p < .01 in C carriers, Figure 21). 
Supplementary Questionnaire: Exploratory Analyses. 
 A series of two-sample t-tests was conducted, where CRP and Hcy blood levels 
were continuous independent variables, and survey responses the grouping variable on 
dichotomous yes/no questions, the results of which are summarized in Table 18. 
Significant t-test results were followed by linear regressions conducted separately by 
group (e.g., yes/no responses) with the significant blood biomarker as the continuous 
independent variable and each cognitive factor examined as the dependent variable in 
turn. Survey responses measured continuously (e.g. duration of medication use, daily 
intake of caffeine or alcohol consumption) were examined with CRP and Hcy blood 
levels using Pearson’s correlations.  
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Figure 19 
N-back Errors and C-Reactive Protein by Sex 
C-Reactive Protein (mg/L)
0 2 4 6 8 10
Er
ro
rs
 
(Lo
g 
Tr
an
sf
o
rm
ed
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Women
Men
 
 
 
Figure 20 
 
N-back Errors by CRP/MTHFR Polymorphism Carrier Status 
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Figure 21 
 
N-back Errors and Age by CRP Polymorphism 
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Vitamin/nutrition supplementation. Neither current nor past vitamin use was 
associated with either CRP or Hcy blood levels (t’s < 1.69).  However, when the 
responses were examined in further detail by type of vitamin use (e.g., multivitamin, 
vitamin B), current use of a multivitamin was associated with lower CRP blood levels 
compared to non-users (1.72 ± 1.44 vs. 2.71 ± 2.61, t = -2.21, p < .05). This difference 
was not bore out in relation to cognition however, as none of the regression analyses 
was significant. There was a trend however for multivitamin users to perform worse on 
the ‘g’ factor than non-users (β = -.28, p < .07 vs. β = -.04, ns). No relationship was 
found for current or past use of a B complex vitamin (t’s < 1.35).  With regard to length 
of time on a vitamin supplement, neither current nor past multivitamin duration were 
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Table 18 
Means and Standard Deviations of Supplementary Questionnaire Responses 
 C-Reactive Protein (mg/L) Homocysteine (µmol/L) 
Variable ‘Yes’ ‘No’ t ‘Yes’ ‘No’ t 
Current Vitamin Use  1.90 ± 1.53 2.66 ± 2.71 -1.69 8.30 ± 1.60 8.47 ± 1.66 -.52 
       Vitamin B Use 2.50 ± 1.86 2.25 ± 2.25 .30 8.14 ± 1.16 8.41 ± 1.66 -.45 
       Multivitamin Use 1.72 ± 1.44 2.71 ± 2.61 -2.21 8.31 ± 1.66 8.45 ± 1.60 -.43 
Vitamin Deficient 2.59 ± 2.61 2.11 ± 1.97 1.00 7.91 ± 1.62 8.63 ± 1.58 -2.06 
Frequent Protein Intake 2.40 ± 2.19 1.58 ± 2.23 1.32 8.37 ± 1.57 8.48 ± 1.92 -.25 
High Cholesterol 2.20 ± 2.15 2.30 ± 2.29 -.20 8.55 ± 1.50 8.13 ± 1.81 1.21 
Prescribed Antilipidemic 1.94 ± 1.62 2.40 ± 2.45 -.95 8.84 ± 1.53 8.14 ± 1.64 2.00 
Diagnosis Unmedicated 2.56 ± 2.64 2.11 ± 2.01 .88 8.20 ± 1.38 8.46 ± 1.72 -.68 
Inflammatory Medication 2.58 ± 2.29 1.67 ± 1.96 1.91 8.37 ± 1.61 8.41 ± 1.69 .13 
       NSAID Use 2.35 ± 2.28 1.93 ± 2.02 .91 8.50 ± 1.64 8.38 ± 1.62 .37 
       Acetaminophen Use 1.57 ± 1.26 2.27 ± 2.28 -1.07 8.40 ± 1.74 8.45 ± 1.61 .11 
Current Alcohol Use 2.37 ± 2.21 1.93 ± 2.22 .80 8.20 ± 1.54 9.02 ± 1.77 -2.07 
Current Caffeine Use 2.45 ± 2.33 1.41 ± 1.20 1.73 8.47 ± 1.63 7.99 ± 1.59 1.08 
Current Smoking 2.62 ± 2.03 2.22 ± 2.24 .56 9.22 ± 1.58 8.28 ± 1.61 1.84 
Current Exercise 2.17 ± 2.05 2.74 ± 2.88 -.94 8.51 ±1.59 7.79 ± 1.71 1.63 
       Aerobic 2.14 ± 1.93 2.43 ± 2.59 -.58 8.44 ± 1.56 8.07 ± 1.78 .97 
       Strength/Resistance 1.96 ± 1.68 2.30 ± 2.24 -.66 8.25 ± 1.78 8.37 ± 1.58 -.32 
       Stretching 2.16 ± 2.11 2.23 ± 2.13 -.12 8.08 ± 1.45 8.40 ± 1.66 -.72 
Infection History 2.09 ± 2.00 2.60 ± 2.45 -1.04 8.35 ± 1.58 8.24 ± 1.69 .29 
Inflammation History 3.03 ± 2.26 1.97 ± 2.17 2.11 8.74 ± 1.58  8.13 ± 1.57 1.69 
Hormone Use History 2.45 ± 2.34 2.78 ± 2.98 -.39 7.74 ± 1.41 9.26 ± 1.64 -3.06 
       Hormone Replace 1.79 ± 1.65 2.65 ± 2.63 1.33 8.17 ± 1.31 8.11 ± 1.73 .13 
       Birth Control 2.37 ± 2.27 2.21 ± 2.39 .25 7.77 ± 1.53 8.61 ± 1.51 -1.94 
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associated with CRP or Hcy blood levels (r’s < -.33, n = 32). Similarly, the time since 
vitamin use was discontinued was also unrelated to blood biomarker levels (r’s < .14, n 
= 12). Neither current nor past vitamin B use duration could be examined, as too few 
people reported this (n = 3 for current, n = 1 for past). 
To the question “have you ever been told you have a vitamin or nutritional 
deficiency,” a positive endorsement was associated with lower Hcy levels (7.91 ± 1.62 
vs. 8.63 ± 1.58, t = 2.06, p < .05). Regression analyses indicated Hcy levels in 
vitamin/nutritionally deficient persons was associated with better performance on the ‘g’ 
factor (β = .44, p < .05 vs. β = -.08, ns). None of the other regression analyses were 
significant (p’s > .11). 
With regard to protein intake, there was no association between CRP or Hcy 
blood levels and a positive endorsement of characterisitically eating a lot of meat or 
other protein (t’s < 1.32). Similarly, reported daily protein intake as estimated by number 
of portions was unrelated to blood biomarker levels (r’s < -.04, n = 84).  
 Medications. Neither CRP nor Hcy blood levels were related to a diagnosis of 
hypercholesterolemia or the diagnosis of hypercholesterolemia in the absence of a 
current anti-lipidemic prescription (t’s < 1.21). However, for those persons with a 
diagnosis and currently prescribed an anti-lipidemic, Hcy levels were elevated 
compared to those persons who were not (8.84 ± 1.53 vs. 8.14 ± 1.64, t = 2.00, p < .05). 
This difference was not bore out in relation to significant regression analyses on 
cognition (all p’s > .16). Pearson’s correlations revealed no significant associations with 
blood biomarkers in terms of the time since a diagnosis of hypercholesterolemia was 
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made (r’s < .01, n = 45) or the duration of treatment with an anti-lipidemic (r’s < .36, n= 
24). 
Use of an anti-inflammatory medication was not associated with CRP or Hcy 
blood levels (t’s < 1.91). This was true regardless of whether participants were taking 
nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, t’s < .91) or those containing 
acetaminophen (e.g., Tylenol, t’s < 1.07). There was a nonsignificant association with 
anti-inflammatory use and CRP levels, such that CRP blood levels were higher in those 
persons taking an anti-inflammatory medication versus those who were not (2.58 ± 2.29 
vs. 1.70 ± 1.96, t = 1.91, p = .06).  However, there was no association between the 
duration of the treatment with an anti-inflammatory medication and blood biomarker 
levels (r’s < -.12, n = 27). 
Alcohol/caffeine consumption. With regard to alcohol consumption, current 
alcohol use was associated with lower Hcy blood levels compared to abstainers (8.20 ± 
1.54 vs. 9.02 ± 1.77, t = -2.07, p < .05). Although none of the regression analyses on 
cognition were significant (p’s > .06), there was a trend for Hcy levels to be associated 
with a faster processing speed among persons who currently drink alcohol relative to 
abstainers (β = .22, p < .07 vs. β = .35, ns). The estimated daily intake of alcohol in 
number of drinks was unrelated to blood biomarker levels (r’s < -.12, n = 86), as was the 
number of years of alcohol use (r’s < .13, n = 71). Neither current nor former caffeine 
consumption was associated with CRP or Hcy blood levels (t’s < 1.73). Similarly, 
estimated daily caffeine intake and number of years of caffeine use were also unrelated 
to blood biomarker levels (r’s < .07, n = 82 and r’s < .12, n = 74 respectively).  
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 Cigarette/tobacco use. Although not significant, there was a trend for current 
smoking to be associated with Hcy blood levels, such that Hcy levels were higher 
among smokers than non-smokers (9.22 ± 1.58 vs. 8.28 ± 1.61, t = 1.84, p = .07). As 
with all the previous analyses, estimated daily intake (in number of cigarettes) and 
duration of smoking history were unrelated to CRP and Hcy levels (r’s < -.21, n = 79 and 
r’s < .37, n = 34 respectively). 
 Exercise/physical activity. Current exercise was unrelated to either CRP or Hcy 
levels (t’s < 1.63). This was true regardless of whether the exercise consisted of aerobic 
exercise, strength/resistance training, or stretching (all t’s < 0.97). On the other hand, 
estimated body type (e.g., overweight, underweight, normal-weighted) was associated 
with Hcy blood levels, such that persons self-described as overweight had lower Hcy 
levels than those who considered themselves normal-weighted (8.05 ± 1.58 vs. 8.78 ± 
1.49, t = 2.19, p < .05). Self-described underweighted individuals were not included in 
these analyses, as there were too few cases (n = 5). Though not significant, there was a 
trend for persons self-described as overweight, to have higher CRP levels than those 
who considered themselves to be normal-weighted (2.74 ± 2.22 vs. 1.85 ± 2.20, t = 
1.86, p < .07). The significant difference in Hcy levels by body type was associated with 
‘g’, such that Hcy levels in normal-weighted individuals was associated with better ‘g’ 
performance compared to over-weight persons (β = .38, p < .05 vs. β = -.14, ns).  
Neither the frequency (number of exercise occasions) nor the duration (in minutes per 
exercise occasion) were associated with blood biomarker levels, either as a whole or by 
exercise type (r’s < -.16, n ≈ 80). The estimated discrepancy between an individual’s 
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body weight and normal-weighted (in pounds) was also unrelated to blood biomarker 
levels (r’s < .31, n = 81).  
 General health. Neither a current nor past history of an infection was associated 
with CRP or Hcy blood levels. Similarly, neither the duration (r’s < .18, n = 43) nor the 
length of time since the most recent infection (r’s < -.27, n = 46) was associated with 
CRP or Hcy blood levels. Though a current inflammatory condition was not related to 
CRP levels (t = 0.95), when any history (either current or past) was compared to no 
history of an inflammatory condition, higher CRP levels were noted among those with 
any history (3.03 ± 2.26 vs. 1.97 ± 2.17, t = 2.11, p < .05). This difference was unrelated 
to cognitive function (p’s > .09). Neither the length of time of the inflammatory condition 
(r’s < -.22, n= 20), nor the time since the most recent inflammatory condition was related 
to blood biomarker levels (r’s < .67, n = 6). 
 Estrogen use.  Current use of hormones (either hormone replacement therapy 
or birth control) was unrelated to CRP or Hcy levels (t’s < 0.47). However, when any 
history of hormone use was compared to no history, a history was associated with 
reduced Hcy levels (7.74 ± 1.41 vs. 9.26 ± 1.64, t = -3.06, p < .01). This difference was 
substantiated on cognitive function as well, such that a past history of hormone use was 
associated with reduced processing speed relative to never users (β= .28, p < .05 vs. β 
= -.13, ns). When the sample was examined for past history dependent on the type of 
hormone (e.g., HRT or birth control), no significant differences emerged. However, there 
was a trend for birth control users to have lower Hcy levels than non-users (7.77 ± 1.53 
vs. 8.61 ± 1.51, t = -1.94, p < .06).  
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CHAPTER 4 
DISCUSSION 
Summary of Results 
Relationship of CRP and Hcy blood levels to cognition. The results of this 
study showed neither CRP nor Hcy were independently associated with poorer 
cognitive performance on any of the cognitive factors measured. Rather, and as 
expected, age was a significant predictor of reduced processing speed, better ‘g’ 
performance, fewer prose memory items recalled, fewer correct name-space creature 
associations, and reduced accuracy in both models. The only other significant predictor 
occurred in the GLM conducted on CRP alone, where hypertension diagnosis was 
associated with reduced processing speed. Though not significant, a few trends 
emerged, such that higher levels of CRP and lower levels of Hcy were associated with 
poorer prose recall, and this was particularly true of men with regard to CRP blood 
levels.  
Elevated CRP blood levels have most frequently been associated with 
performance decrements on measures of global cognition, though decrements have 
been observed in other areas as well (see Tables 1 and 2). For those studies which 
specifically assessed declarative memory, only three studies examined prose recall 
(Rafnsson et al., 2007; Shawcross et al., 2007; Suzuki et al., 2006), and of the three, 
only one of which (Shawcross et al., 2007), found a negative correlation between CRP 
blood levels and prose recall. In that study, deterioration on prose recall following an 
amino acid load (a model of hyperammonemia) was associated with markedly elevated 
levels of inflammatory markers, including CRP. However, all the participants had biopsy 
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proven cirrhosis of the liver with inflammatory markers indicating the presence of an 
acute inflammatory condition and thus are not a suitable comparison group to a healthy 
aging sample as in the present study. Thus the findings with CRP in relation to prose 
recall are in accord with the majority of studies conducted. 
Performance decrements in relation to elevated CRP blood levels in the literature 
have not been limited to declarative memory. However, a direct comparison of previous 
findings with those of the present study is precluded given several methodological 
differences. The majority of studies have been conducted on age-restricted populations 
(≥ 50 years), persons with overt inflammatory conditions (e.g., systemic lupus 
erythematosus, peripheral arterial disease, coronary artery bypass graft or valvular 
surgery), or patient populations (e.g., schizophrenics). Only one study (Teunissen et al., 
2003) has observed performance decrements among elevated CRP levels in a normal 
aging lifespan sample. In the Teunissen et al. (2003) study however, exclusion criteria 
were minimal, and the range of CRP values was much broader than the current study 
(0.5 – 27.83 mg/L) thereby including persons with an acute inflammatory condition. In 
the present study, the inclusion of persons with CRP levels ≥ 10 mg/L did not result in 
any significant associations between CRP levels and cognitive function (all r’s < ± .11).  
With regards to Hcy, the literature has identified impairments across a broad 
array of cognitive domains including declarative memory (see Tables 3, 4 and 5). As 
with CRP however, many of these studies have been conducted on age-restricted 
populations, persons with overt disease, or among patient populations. Of those studies 
conducted on a lifespan sample (Elias et al., 2006; 2008; Teunissen et al., 2003; Wright 
et al., 2004), performance decrements have been observed for global cognition, 
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psychomotor speed, visuospatial ability, declarative memory, reasoning, and executive 
functions. However, as was the case with CRP, inclusion criteria across the studies 
were minimal, with large percentages of the samples being diagnosed with conditions 
known to alter Hcy levels (e.g., cardiovascular disease, diabetes, vitamin B deficiency). 
Moreover, in the Wright et al. (2004) study, about half the sample had less than a high 
school education, many of whom additionally had MMSE scores consistent with a 
diagnosis of mild cognitive impairment or dementia. Lastly, the range of Hcy values was 
considerably larger than that of the present study, and all studies included values that 
met criteria for hyperhomocysteinemia. Indeed, in the Elias et al samples (2006; 2008), 
20% of the sample had Hcy values higher than the uppermost point of the range (11.8 
µmol/L) in the present study. Similarly, in the Wright et al. (2004) study, 10% of the 
sample had values ≥ 15 µmol/L. In this regard, there may have been an apparent bias in 
previous studies to find a significant negative correlation between Hcy and cognitive 
function, as values were well outside the normal range and may be indicative of 
subclinical cardiovascular disease. 
It may be the case that elevated Hcy levels in and of themselves are not 
problematic. Rather, elevations in Hcy are concomitant with conditions known to affect 
cognitive function (e.g., cardiovascular disease), and it may be the underlying disease  
process rather than elevated Hcy levels per se that are responsible for impairments in 
cognitive functioning. Given Hcy levels are a graded risk factor for cardiovascular 
disease (Refsum, Ueland, Nygård, & Vollset, 1998), there may be subclinical factors at 
work in persons with Hcy elevations, despite a lack of overt cardiovascular disease.   
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Indeed, in the present study of exceptionally healthy adults, although there were 
no effects of Hcy levels on cognition, the one trend observed was for an improved 
performance on prose recall. This is in accord with one other study which found a 
positive effect of elevated Hcy levels on the Logical Memory task. Namely, persons with 
an impaired Logical Memory performance had significantly lower Hcy levels than 
persons with normal performance (Frieling et al., 2005). However, this sample was 
considerably younger than the current study (mean ~ 25 years) and was comprised of 
persons with a diagnosis of either anorexia or bulimia nervosa, two eating disorders that 
should theoretically result in nutritional deficiencies and subsequent higher Hcy levels, 
so it is unclear how well the results generalize to the current study. 
Relationship of CRP and Hcy blood levels to each other. The second 
hypothesis postulated that CRP and Hcy blood levels would be moderately correlated 
with one another. This was not the case.  A nonsignificant and negative correlation was 
found for both the reduced sample and the total sample. Restriction of the analyses to 
either persons with CRP levels ≥ 10 mg/L or persons with Hcy levels ≥ 12 µmol/L, 
strengthened the association, but the correlation remained nonsignificant. Only when 
the analyses were restricted to persons with elevations in both, did a significant 
negative correlation ensue. This is in accord with several studies which found no 
association between CRP and Hcy levels (Fischer et al., 2006; Gunstad et al., 2006; 
Ravaglia et al., 2005; Silbert et al., 2008). On the other hand, several studies have 
shown CRP and Hcy blood levels are significantly and positively correlated with one 
another (Holven et al., 2006; van den Kommer et al, in press; Youssef et al., 2007) 
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however, these studies were conducted in hyperhomocysteinemic persons with overt 
cardiovascular disease.  
Regardless of whether or not the previous literature has found the correlation 
between CRP and Hcy to be significant, all studies agree that the two variables are 
positively related to one another. There are several potential explanations for this. As 
has previously been discussed, there are differences in the samples with regards to the 
range of CRP and Hcy values. In the Holven sample (2006), the correlation was only 
significant among hyperhomocysteinemics, who had Hcy levels as high as 75 µmol/L. In 
the Youssef et al., study (2007), correlations between CRP and Hcy were evidenced 24 
hours post-stroke, where inflammatory mechanisms and hence CRP levels are 
expected to be high. Both of which suggest the positive correlation is only found when 
one or the other is elevated outside the normal range, but not both. 
A second possibility pertains to the assays used, their lower detection limits, and 
the coefficient of variation in their day-to-day analytical precision. With regards to CRP, 
the vast majority of emerging studies use a high-sensitivity immunonephelometric assay 
(hs-CRP), unlike the current study which used the immunoturbidmetry method (imCRP). 
The conventional imCRP method although suitable for the measurement of CRP 
concentrations during infection, has a lower detection limit far less sensitive than the 
newer hs-CRP method (≥ 3 mg/L versus > 0.1 mg/L) and could thus potentially fail to 
detect values below a certain threshold, particularly in a healthy sample where values 
are lower. For this reason, the imCRP method has been regarded as unsuitable for 
CRP values within the normal reference range (< 10 mg/L) in recent years (Ledue & 
Rifai, 2003). But given CRP levels in the current study were detected as low as 0.1 
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mg/L and 41% of the values in this sample were 1 mg/L or less, it would indicate there 
was not a failure of detection. At worst, it may be an issue of sensitivity, such that CRP 
levels may be overestimated, thereby making the effects of elevated CRP levels more 
readily observed. However, given no significant effects of CRP were found, this is likely 
not a concern.  
Differences in sensitivity may also be an issue when comparing across studies. 
Lower detection limits have been reported as low as 0.8 ng/mL (van den Kommer et al., 
in press) to as high as 0.5-1.0 mg/dL (Gunstad et al., 2006). According to one study, 
more than 97% of healthy adults have CRP values less than 0.5 mg/dL (Ravaglia et al, 
2005). If this is true, depending on the assay used, many measurements may fall 
outside the detectable limits thereby causing a range restriction to higher levels. With 
regards to Hcy, the assays of choice have typically been either fluorescence 
polarization immunoassay (FPIA), or high-performance liquid chromatography (HLPC). 
As with CRP however, there are distinct differences in precision. In a study by Ubbink, 
Delport, Riezler and Vermaak (1999), four different assays of plasma Hcy were 
compared including FPIA and HPLC. Mean tHcy concentrations were measured a full 
µmol/L higher using the FPIA method versus HPLC. However, the coefficient of 
variation in inter-measure analytical precision was considerably better for the FPIA 
versus the HPLC assay (4.5% vs. 8.4%). Hcy also has special handling procedures 
which require samples to be drawn in the fasting state, immediately placed on ice, and 
centrifuged within one hour (Refsum et al., 2004). Failure to adopt these practices 
unnecessarily inflates Hcy levels in a manner completely removed from differences in 
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sample characteristics, all of which point to the inherent difficulty in generalizing across 
studies.  
Combined effect of elevated blood levels of CRP and Hcy on cognition. 
Although neither CRP nor Hcy had a significant effect on cognition independently, when 
both terms were entered into a GLM, a nonsignificant trend for CRP × Hcy on 
psychomotor speed was found, such that high Hcy levels, but low CRP levels, were 
associated with reduced processing speed. Additional significant interactions for Hcy 
with age on psychomotor speed and with sex on prose memory were also identified. In 
terms of the domains affected, the results are consistent with the one study conducted 
thus far that has looked at the combined impact of elevations in both CRP and Hcy 
blood levels.  
In the Longitudinal Aging Study Amsterdam (LASA), CRP had a modifying effect 
on longitudinal rate of decline for processing speed, such that persons with a high tHcy 
showed the fastest rate of decline for the lowest and middle tertiles of CRP (van den 
Kommer et al., in press). In the current study, slowing of psychomotor speed was 
associated with older age, and higher blood levels of Hcy, but only among the most 
aged. Among younger persons, higher Hcy levels were actually associated with faster 
response times, while lower levels were associated with universally slower response 
times, regardless of age. Among persons with elevated CRP, response time was fastest 
when Hcy levels were low. Conversely, among persons with elevated Hcy, response 
times were slowest when CRP levels were low.  
Persons with the highest tertile of CRP who also had a high level of tHcy also 
performed the worst on delayed recall of a verbal learning task in the LASA study (van 
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den Kommer et al., in press). For prose memory in the current study, a main effect of 
Hcy was identified in the absence of a significant post-hoc beta (β = .06, ns). The 
direction of the beta suggested however that higher levels of Hcy were associated with 
better prose memory performance, and this was particularly true of men who showed 
better recall than women with higher Hcy levels. The fact that Hcy carried a beta in the 
opposite direction to that of age and it’s inclusion in the GLM added additional variance 
explained over that of age alone (β = -.26, p = .005 vs. β = -.22, p = .007) however, 
indicates that age has a suppressor effect on Hcy.  As age in itself is associated with 
cardiovascular risk, and Hcy levels increase with age (Refsum et al., 2004), such an 
argument is not outside the realm of possibility. Indeed, when age and Hcy were 
included in the post-hoc regression, the beta for Hcy approached significance (β = .15, 
p = .08).  
 Substantial differences exist between the LASA sample and the current study 
however which may in part explain the discrepant results. The LASA study is comprised 
of adults over the age of 65 years, with a mean education of less than the 9th grade and 
a high prevalence of hypertension, cardiovascular disease, and hyperhomocysteinemia. 
Compare this to a lifespan sample, with a mean education nearing 4-years college, a 
prevalence of hypertension less than half that of LASA, and a complete absence of 
cardiovascular disease and hyperhomocysteinemia, Moreover, not only were 
hyperhomocysteinemics excluded, but male sex is a risk factor for elevated Hcy levels 
(Refsum et al., 2004), a group who was underrepresented in the present sample 
(~30%), and hence their relative absence may have driven down the mean Hcy level 
further. 
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Relationship of T allele carrier status to blood levels of CRP and Hcy. 
Neither T carrier status for CRP or MTHFR was associated with higher blood levels of 
their respective blood biomarker. Although for the CRP gene, T carrier status had higher 
blood levels than the referent C carriers, the difference was not significant (t = .74, ns). 
When C/T heterozygous carriers were excluded, the difference was larger but remained 
non-significant (t = 1.31, ns). On the other hand, A carrier status was associated with 
the highest CRP levels. This is in accord with one study in which A and T homozygosity 
was associated with higher CRP levels, but only among non-Hispanic blacks. Among 
Hispanics, T homozygotes were associated with higher CRP levels, whereas in non-
Hispanic whites, CRP blood levels were not different among any polymorphism 
(Crawford et al., 2006). In the present sample, no participants were homozygous for the 
A allele, thus, when A carrier status was compared to C homozygous carriers, the result 
approached significance in blacks, but not whites (t = 1.89, p < .08 vs. t = 0.56, ns). A 
similar relationship did not exist for T homozygosity in either blacks or whites (t = 0.67, 
ns in blacks, vs. t = 1.25, ns for whites). The reason for the discrepancy may be 
because in the current sample, African Americans were underrepresented as a group, 
particularly those homozygous for the T allele (n = 3). 
Quite unexpectedly, for the MTHFR allele, T carrier status was associated with 
the lowest Hcy blood levels. In previous studies, homozygosity for the T allele has been 
associated with the highest Hcy levels (Albert et al., 2009; Dedoussis et al., 2005), 
particularly among males (Kluijtmans et al., 2003), while in women, the MTHFR 667C>T 
variant is related to Hcy levels in Caucasians, but not among black, Asian, or Hispanic 
women (Albert et al., 2009). In the current study, the highest Hcy levels among men 
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were for C/T heterozygotes, and for women, C homozygotes. For both sexes, T 
homozygotes had the lowest Hcy blood levels. For both blacks and whites, the highest 
Hcy levels were found in C homozygotes, followed by C/T heterozygotes. There were 
no African Americans homozygous for the T allele. 
Genetics studies examining population differences require large numbers of 
participants. The current sample was considerably underpowered to study differential 
genetic distributions in Caucasians or African Americans given the number of variants 
(particularly for CRP) and the prevalence of the minor variants in the general population. 
However, as T carriage is more prevalent among persons with cardiovascular disease 
(Klerk et al., 2002) and VaD (McIlroy et al., 2002), it may be the case that the inclusion 
criteria for the current study necessarily selected out the T homozygotes. 
Relationship of T allele carrier status to cognition. With regards to the CRP 
gene, in addition to the significant age and population effects across all domains, 
significant effects of CRP were found in relation to psychomotor speed and ‘g’/inhibition. 
As no studies have examined the -286 CRP C>T>A gene in relation to cognition, it is 
hard to frame the findings within the context of the literature. However, the one study to 
examine CRP SNPs found the minor allele variant of 1059 G>C was associated with 
cognitive deficits post cardiopulmonary bypass surgery on a composite of several 
cognitive domains (psychomotor speed, visuospatial ability, attention, declarative 
memory, executive functions). In the present study, T allele status was associated with 
reduced processing speed compared to either A carriers or C homozygotes. With 
regards to ‘g’/inhibition, both inter and intra-sex differences were evident. Among A 
carriers, men performed better than women, whereas in T carriers, the opposite was 
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true. Men with the A allele also performed better than C homozygous women. In 
women, T carrier status was associated with better performance than C homozygosity, 
whereas in men, A carrier status was associated with better performance than either T 
carrier status or C homozygosity.  
With regards to MTHFR, allele status was a significant interaction term in 
combination with age and hypertension for prose memory. With older age, carriers of 
the T allele recalled more items than C homozygotes. Several studies have observed no 
detriment in relation to T carrier status (Bottiglieri et al., 2001; Flicker et al., 2004; 
Gussekloo et al., 1999; Matsui et al., 2001; Nurk et al., 2005; Ravaglia et al., 2004a; 
Rodriguez-Oroz et al., 2009), and indeed, two studies have shown a benefit to T 
carriage on measures of processing speed (Araki et al., 2003; Durga et al., 2006). 
However the latter of these studies recruited only persons with elevated Hcy (> 13 
µmol). Thus, the sample included a disproportionate number of T homozygotes 
compared to other samples, and could have been affected by upwardly biased selection 
of survivors.  
Conversely, among hypertensives in the current study, T carriage was 
associated with the fewest items recalled, whereas T carriage in normotensives was 
associated with the most items recalled. This is in accord with a previous study in which 
spatial navigation performance was impaired among hypertensive T carriers (Deshmukh 
et al., 2009). More generally, as both hypertension and T carrier status are vascular risk 
factors, it may be the case that multiple risk factors confer an additive risk for poor 
cognitive performance, whereas T carrier status alone in the absence of other vascular 
risk factors is not detrimental. 
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Combined effect of T allele carrier status for both CRP and MTHFR on 
cognition. When both SNPs and their respective blood biomarkers were entered into 
the GLM, several of the same trends were obtained as when each SNP was entered 
into separate GLM analyses, albeit for the most part, they were no longer significant. 
For psychomotor processing speed, the T allele of the CRP SNP was associated with 
reduced speed, whereas for ‘g’/inhibition, A carriage among males was associated with 
better performance than A carriers in women, C homozygosity in either men or women, 
and T carriers in men. In women on the other hand, T carriage was associated with 
better performance than either T carriers in men or C homozygotes in women. Although 
not significant, the Age × CRP for accuracy showed a trend such that with older age, A 
carriers made the most errors, and T carriers the least, with C homozygotes making an 
intermediary number of errors.  
For the MTHFR SNP, the same Age × MTHFR interaction for prose memory was 
found, such that with older age, fewer items were recalled for C homozygotes compared 
to T carriers. An additional trend for an interaction between the MTHFR SNP and Hcy 
was found such that with higher Hcy levels, T carriers recalled fewer items than C 
homozygotes.  
The one point of interaction for the two SNPs was for accuracy, where a non-
significant trend emerged. Accuracy was lowest among A carriers of the CRP SNP and 
T carriers of the MTHFR SNP. Conversely, T carriage for both CRP and MTHFR was on 
the high end of accuracy and only made more errors than C homozygotes on the CRP 
SNP who were T positive for MTHFR. 
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Supplementary questionnaire exploratory analyses. In the supplementary 
analyses, few variables were related to CRP and Hcy blood levels. Namely, lower CRP 
levels were associated with current multivitamin use, whereas higher CRP levels were 
associated with a past history of an inflammatory condition versus no history. Among 
Hcy levels, lower levels were associated with being told of a nutritional or vitamin 
deficiency, current alcohol use, a past history of hormone use, and having a self-
described overweight body type; whereas higher Hcy levels were associated with being 
prescribed an anti-lipidemic for high cholesterol.  
Several studies support an association between CRP blood levels and lifestyle 
factors. Namely, elevated CRP levels are observed with vigorous exercise, current 
smoking, increased body mass index, abstinence or infrequent alcohol use, and current 
hormone therapy (Ledue & Rifai, 2003).  In the present study, neither exercise as a 
whole nor exercise by subtypes was associated with elevations. This may be because 
in the current study, aerobic exercise consisted of any type of exercise in which heart 
rate may be expected to be elevated (e.g., walking, running, elliptical machine). 
However, there was no objective measure of whether or not exercise was of sufficient 
intensity to elevate heart rate, so some people may have been misclassified as aerobic 
exercisers. On the other hand, strength/resistance training and stretching are not 
considered vigorous, so it is not surprising that CRP levels were lower in relation to 
these. However, in accord with previous findings, current smoking, a self-described 
overweight body type, and current birth control use were associated with higher CRP 
levels, though not significantly. 
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Conversely, lower CRP levels have been associated with statin use for the 
treatment of high cholesterol, moderate alcohol consumption, and use of an anti-
inflammatory medication (Ledue & Rifai, 2003). Although a diagnosis of high cholesterol 
should result in higher CRP levels, this was not the case in the present study. Further 
examination suggested that many of the persons with a diagnosis of high cholesterol 
were also on lipid lowering medications, which should result in lower CRP levels. It may 
be the case then that treated persons in effect had lower cholesterol levels and thus 
lower CRP levels. Indeed, among those with a diagnosis and no prescription, CRP 
levels were higher. With regard to alcohol use, although the majority of the sample 
reported drinking, about 80% did not consume alcohol on a daily basis, thus higher CRP 
levels may be expected. Use of an inflammatory medication was associated with higher 
CRP levels. This is interesting given NSAIDs are prescribed for inflammation reduction. 
It may be the case however that persons who use inflammatory medications have 
higher baseline CRP levels than those who do not, and the result may be a net 
reduction in CRP levels, but not below those of persons without a need for anti-
inflammatory medication. 
Given CRP is a marker of inflammation (Black et al., 2004), it is of no surprise 
that persons indicating any type of history of an inflammatory condition had higher CRP 
levels than those indicating no such history. It was expected that a similar relationship 
would exist for those persons indicating a past history of infection, as CRP is an acute 
phase reactant and increases markedly to such insults to the body (Black et al., 2004), 
but this was not the case. Responses to the type of past infection were highly variable 
however, with participants indicating anything from the presence of minor colds and 
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sore throats, to hepatitis C. More than likely, persons indicating no past history of 
infection failed to report such minor infections, and a simple dichotomous division was 
not specific enough to accurately assess infection history.  
B vitamins though essential for the 1-carbon metabolism cycle have also been 
inversely related to CRP levels in a large population study (Friso, Jacques, Wilson, 
Rosenberg, & Selhub, 2001), and to reductions in CRP levels in a randomized placebo-
controlled trial (Church, Earnest, Wood, & Kampert, 2003). Although vitamin B itself was 
not predictive of CRP levels, more than likely as a result of power (n = 8), use of a 
multivitamin was.  
With regards to Hcy, vitamin B deficiency has been associated with elevations in 
Hcy levels (Refsum et al., 2004). Interestingly, being told of a vitamin or nutritional 
deficit was associated with significantly reduced Hcy levels in the present study. 
However, the deficiencies reported only included deficiencies in vitamin K, vitamin D, 
and iron. Indeed, vitamin B levels (folate and vitamin B12) as measured in the present 
study were not indicative of a deficiency. Along these same lines, supplementation with 
vitamin B has been shown to reduce Hcy levels (Refsum et al., 2004), which was also 
the case in the present study. Although not significant, both vitamin B and multivitamin 
supplementation resulted in lower Hcy levels. Conversely, diets rich in protein have the 
effect of elevating Hcy levels (Refsum et al., 2004). In the present study, the habit of 
characteristically eating a lot of meat or other protein was associated with lower Hcy 
levels however. This may have been attributed to the interpretation of ‘a lot’ however, as 
responses to this varied anywhere from less than daily intake, to 10 portions per day. 
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With regard to lifestyle factors, elevated Hcy levels are associated with smoking 
and caffeine consumption, whereas exercise and alcohol intake have been associated 
with both increased and decreased Hcy levels (Refsum et al., 2004). In the current 
study, albeit not significant, both smoking and caffeine intake were associated with 
higher Hcy levels. With regards to exercise, low impact activities such as strength 
training and stretching were associated with non-significant lower Hcy levels, whereas 
exercise as a whole and aerobic activity were associated with non-significant increases. 
On a related note, an overweight self-described body type was associated with 
significantly lower Hcy levels compared to self-described normal-weighted individuals. 
Alcohol was related to lower Hcy levels in the present study, perhaps in par with studies 
that have shown alcohol in moderation is associated with reduced risk for heart disease, 
peripheral vascular disease, and stroke.  
As Hcy is a cardiovascular risk factor and is associated with the development of 
atherosclerosis (Seshardi, 2006), it is logical for there to be an association with 
cholesterol levels. Indeed, in the present sample, cholesterol diagnosis was associated 
with higher Hcy levels compared to persons without a diagnosis. Use of an anti-
lipidemic was associated with significantly higher Hcy levels, perhaps because 
cholesterol levels may be high enough to warrant treatment with medication, whereas 
among persons who are told they have high cholesterol and are not medicated may 
only be borderline high. Indeed, persons who had a diagnosis but were not prescribed 
an anti-lipidemic had non-significantly lower Hcy levels. 
Use of estrogen post-menopausally has been shown to decrease Hcy levels 
(Refsum et al., 2004). In the current study use of a hormone was associated with 
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significantly lower Hcy levels, but interestingly, hormone replacement therapy in post-
menopausal women was related to higher Hcy levels, whereas birth control was related 
to lower levels. 
General Discussion 
 
Quite contrary to the majority of the previous research, there was not a negative 
effect of elevated blood levels of CRP or Hcy. Also in contrast to previous literature, 
there was not a detrimental effect to being a T carrier, except perhaps for psychomotor 
processing speed and in conjunction with male sex on ‘g’ for the CRP SNP, and in 
conjunction with hypertension status on prose recall for the MTHFR SNP. Rather, T 
carrier status in the absence of other vascular risk factors (e.g., hypertension) was 
beneficial to cognitive performance in older persons.  
The discrepancy in results may in large part be due to the stringency in which 
potential participants are selected into the current study relative to other studies. 
Participants in the current study represent the best-case scenario of aging and are free 
of self-reported cardiovascular, neurological, endocrinological, metabolic, and 
psychiatric disease, as well as being free of drug and alcohol abuse, and central acting 
stimulants or depressants. An extensive blood work-up and MRI scans additionally 
support the general health of the sample, as there was no evidence of vitamin 
insufficiency (as defined by folate and vitamin B12 reference range values), or signs of 
stroke or white matter degradation beyond expected with normal aging.  
The current sample also reports a reduced prevalence of various risk factors and 
poor life choices than the national average as polled by a 2008 National Health 
Interview Survey by the Centers for Disease Control and Prevention’s National Center 
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for Health Statistic (Pleis, Lucas, & Ward, 2009). Less than a quarter of the sample had 
either a diagnosis of hypertension or a mean systolic ≥ 140 mmHg and/or diastolic ≥ 90 
mmHg, compared to the national average of 32% among non-institutionalized adults 
over the age of 20 years. Similarly, only 12% of the survey respondents reported 
currently smoking, compared to 21% of United States adults over the age of 18 years. 
The 2008 survey also reports that more than half of the adult U.S. population drank 
alcohol in the past 30 days, with 5% reporting heavy drinking, and 15% reporting binge 
drinking. Contrast that to the present study, where although about 78% of the 
respondents report drinking alcohol, only 20% of those report daily consumption, and 
only one female’s consumption (1%) was high enough to be considered binge drinking. 
Finally, the survey states that 59% of the respondents reported that they had never 
participated in vigorous exercise, compared to 70% in the current sample who reported 
some sort of aerobic activity, and 75% of whom did so at least once weekly. 
 Further, the exclusion of persons with values outside the reference range for 
either CRP or Hcy resulted in a far more homogenous sample than previous studies. 
While this was mainly done in order to understand the relationship of CRP and Hcy 
values to one another, cognition, and genetics without confound of potential inclusion of 
persons with an acute inflammatory condition or hyperhomocysteinemics, it had the 
added benefit of reducing variability among other vascular risk factors and indices of 
health (e.g., systolic and diastolic blood pressure), which also resulted in a better 
educated sample with a higher mean MMSE score. Taken together, these factors 
further attest to the general health of participants in the present study relative to 
previous studies. 
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The inability to detect significant effects of CRP and Hcy may have additionally 
been hampered by the use of the exploratory factor analysis. Although the consideration 
was to reduce the number of dependent variables, the resultant factors may not have 
been particularly representative of the individual tests comprised of these factors, 
particularly for the speed and ‘g’/inhibition factors. Indeed, when the results were 
repeated on each of the individual tests for these factors, additional main effects and 
interactions emerged. Namely, hypertension either as a main effect or in interaction with 
sex emerged as a significant predictor of working memory speed and number of 
comparisons made for both the CRP and Hcy GLMs. Additionally, when CRP and Hcy 
were analyzed in the same model, a significant interaction of CRP × Hcy emerged for 
vocabulary and working memory speed.  
Similarly, in the GLMs conducted with SNPs as a categorical independent 
variable, in addition to a main effect of CRP on working memory speed, several 
interactions of SNP emerged in the analysis conducted on CRP alone or in the 
combined analysis, where CRP interacted with age on CFIT performance, with Hcy on 
vocabulary and working memory speed, with sex on number of perseverative errors, 
and with population on the number of comparisons made. These findings suggest that 
both the effects of blood levels and SNPs may be very specific, and may only be 
observed on select tests or in select subpopulations within the context of fine grained 
analysis, rather than on larger factors. 
One final point of divergence from the literature concerns Hcy levels and 
correction for vitamin B levels. Given the constrained sample to normal CRP and Hcy 
blood levels, folate and vitamin B12 levels were not expected to be lower than the 
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accepted norm, and indeed they were not. However, given the importance of the B-
complex vitamins in the regulation of Hcy, the effect of folate and vitamin B12 were 
examined post-hoc. Neither folate nor B12 were significantly associated with Hcy levels 
or any of the cognitive factors (all p’s > .40). In partial correlations, the removal of folate,  
vitamin B12, or both from the dependent variable(s) resulted in universally stronger 
associations of Hcy with cognition, which were significant for the speed factor (p’s < 
.051) and approached significance for the associative memory factor (p’s < .10).  
However, when Hcy, folate, and vitamin B12 were centered to the mean and 
entered as continuous independent variables along with age, and sex and hypertension 
status as categorical variables in the GLM analyses, differential effects were observed. 
Hcy was a significant predictor of the prose memory and accuracy factors, while folate 
emerged as a significant main effect on the speed and prose memory factors, and 
vitamin B12 was a significant predictor in the ‘g’/inhibition and associative memory 
factors. Interestingly however, with the exception of vitamin B12 which remained 
significant at post-hoc and indicated higher levels were associated with better ‘g’ 
performance and reduced associative memory, no other main effects were significant at 
post-hoc. All effects were trumped by age however, and post-hoc regression analyses 
with age, Hcy, folate, and B12 entered an independent effects were significant for all 
variables and explained an average of .05 more variance than age alone, indicating a 
suppressor effect of age on each of these.    
Limitations and Conclusions 
 There are several limitations to the current study that should be addressed. First, 
although the focus on healthy aging inherently reduced some confounds seen in the 
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literature, it may also be viewed as a limitation, as results do not generalize to a typical 
aging population. Second, the cross-sectional nature of the study precludes making any 
inferences about causality, though few correlations were observed among the variables 
of interest. Third, the relatively small sample size precluded analysis of higher-order 
interactions to further probe the potential association among inflammatory blood 
biomarkers, genetic factors, and cognition. The small sample size also presented a 
challenge for studying genetic variations, particularly as it relates to population effects, 
as polymorphisms of the two genes differ across populations. In the current study, 
African Americans as a group were severely underrepresented, as were specific alleles 
within them. Fourth, many analyses were run which were not corrected for by multiple 
comparisons, so any observed effects are liable to be the result of random error and 
would likely be more conservative if corrected for. Finally, for the supplementary 
questionnaire data, there was a reliance on self-report data. Self-report is often 
unreliable, particularly when probing retrospective memories from extended periods of 
time. Although blood work is available on these participants to corroborate some of the 
information obtained in the supplementary questionnaire (e.g., cholesterol, vitamin 
levels, presence of an infection), this was not explored in the present study.  
 In conclusion, among an exceptionally healthy aging population free of any overt 
signs of cardiovascular disease, normal range elevations in blood levels of CRP or Hcy, 
either alone or in combination, are not associated with cognitive impairments across 
several domains. Moreover, T carriage for either the -286 CRP C>T>A or MTHFR C>T 
SNPs is not associated with blood levels of CRP or Hcy, and is only associated with 
cognition in a task and subpopulation specific manner. Namely, T carriers of the CRP 
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SNP have reduced processing speed, and among men, reduced ‘g’ performance. 
Whereas for the MTHFR SNP, T carriage is associated with fewer prose items recalled 
among hypertensives. Several lifestyle factors may alter CRP and Hcy levels. However, 
their inclusion/exclusion in a sample of this health caliber does not significantly alter 
cognitive outcomes. Based on the evidence, within a healthy sample, subclinical 
inflammatory mechanisms do not appear to exert much control on cognitive outcomes.
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Medications 
 
1. Have you ever been told you have high cholesterol?  Yes      No  
If yes, how long ago were you first told? 
___________________________________________________________________________ 
 
2. Are you currently prescribed an antilipidemic (for high cholesterol)?  Yes       No 
If yes, please list: 
______________________________________________________________________________
_______________ 
 
3. If you currently take an antilipidemic, for how long have you been taking this medication? 
_________________________________ 
Has this been continuous use?  Yes      No  
If no, please explain: 
______________________________________________________________________________
____________ 
 
4. If you do not currently take an antilipidemic, have you ever taken one in the past?  Yes       No    
If yes, please list: 
______________________________________________________________________________
_______________ 
 
5. If you are not currently taking an antilipidemic, but did in the past, for how long did you take 
the medication? _________________ 
Was this continuous use?  Yes         No  
If no, please explain: 
______________________________________________________________________________
____________ 
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Alcohol/Caffeine Consumption: 
1. Do you currently drink alcoholic beverages?   Yes        No  
If yes, how many drinks on average do you have daily? _______________ weekly? 
_______________ monthly? _________________ 
  
2. If you do not currently drink alcoholic beverages, have you ever? Yes       No   
If yes, how many drinks on average did you drink daily? ________________ weekly? 
_______________ monthly? _______________ 
 
3. What type of alcoholic beverages do/did you typically consume?   Beer      Wine       Liquor       
Other ________________________ 
 
A
lcohol/C
affein
e
 C
o
n
su
m
ptio
n
:
 
 1. D
o
 you cu
rrently drink alcoholic
 bev
erages?
 
 
 Y
es
 
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 how
 m
any d
rinks
 o
n
 av
erag
e
 do you hav
e
 daily?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 w
eekly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 m
o
nthly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 
 
2. If
 you do not
 cu
rrently drink alcoholic
 bev
erag
es
,
 hav
e
 you ev
er?
 Y
es
 
 
 
 
 
 
 N
o
  
 
If
 yes
,
 how
 m
any d
rinks
 o
n
 av
erag
e
 did you drink
 daily?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 w
eekly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 m
o
nthly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 3. W
hat
 type
 of
 alcoholic
 bev
erag
es
 do/did you typically co
n
su
m
e?
 
 
 B
eer
 
 
 
 
 
 W
in
e
 
 
 
 
 
 
 Liquor
 
 
 
 
 
 
 O
ther
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
If
 liquor
,
 w
hat
 type?
 
 
 Sh
ot
 
 
 
 
 
 
 C
o
cktail
 (single
 liq
u
o
r)
 
 
 
 
 
 
 
 C
o
cktail
 (m
ultiple
 liquors)
 
 
 
 
 
 
 
 O
ther
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 4. F
o
r
 how
 m
any years
 h
av
e
 you dru
nk alcoholic
 bev
erag
es?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 5. H
as
 the
 n
u
m
ber
 of
 alcoholic
 drinks
 co
n
su
m
ed changed ov
er
 tim
e?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 please
 explain
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 6. Please
 estim
ate
 the
 n
u
m
ber
 of
 o
u
n
ces
 of
 alcohol
 co
n
su
m
ed daily _____________ w
eekly ______
_
_
_
_
_
_
_
 m
o
nthly _____
_
_
_
_
_
_
_
_
 
(shot
 =
 1.5 oz
.;
 co
cktail
 =
 1.5 oz
.
 per
 alcohol;
 standard w
in
e
 glass
 =
 5 oz
.;
 standard beer
 can
 =
 12 o
z;
 a
 pint
 =
 12 oz
.)
 
 
 7. D
o
 you cu
rrently drink caffein
ated b
ev
erages?
 
 
 Y
es
 
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 how
 m
any d
rinks
 o
n
 av
erag
e
 do you hav
e
 daily?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 w
eekly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 m
o
nthly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 8. If
 you do not
 cu
rrently drink caffein
ated b
ev
erages
,
 hav
e
 you ev
er?
 Y
es
 
 
 
 
 
 
 N
o
   
If
 yes
,
 how
 m
any d
rinks
 o
n
 av
erag
e
 did you drink
 daily?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 w
eekly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 m
o
nthly?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 9. W
hat
 type
 of
 caffein
ated bev
erages
 do/did you typically co
n
su
m
e?
 
 C
offee
 
 
 
 
 
 T
ea
 
 
 
 
 
 
 E
n
ergy D
rink     O
ther
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 10. F
o
r
 how
 m
any years
 hav
e
 you dru
nk caffein
ated bev
erages?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
11. H
as
 the
 n
u
m
ber
 of
 caffein
ated d
rinks
 co
n
su
m
ed changed ov
er
 tim
e?
 
 Y
es
 
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 please
 explain
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 12. Please
 estim
ate
 the
 n
u
m
ber
 of
 o
u
n
ces
 of
 caffein
e
 co
n
su
m
ed daily ____
_
_
_
_
_
_
_
_
 w
eekly _____
_
_
_
_
_
_
_
 m
o
nthly _____
_
_
_
_
_
_
_
_
 
(cup =
 6 o
z
.;
 m
ug =
 8 oz
.;
 trav
el
 m
ug =
 16 oz
.)
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Alcohol/Caffeine Consumption: 
1. Do you currently drink alcoholic beverages?   Yes        No  
If yes, how many drinks on average do you have daily? _______________ weekly? 
_______________ monthly? _________________ 
  
2. If you do not currently drink alcoholic beverages, have you ever? Yes       No   
If yes, how many drinks on average did you drink daily? ________________ weekly? 
_______________ monthly? _______________ 
 
3. What type of alcoholic beverages do/did you typically consume?   Beer      Wine       Liquor       
Other ________________________ 
If liquor, what type?   Shot       Cocktail (single liquor)        Cocktail (multiple liquors)        Other 
_____________________________ 
 
4. For how many years have you drunk alcoholic beverages? 
__________________________________________________________ 
 
5. Has the number of alcoholic drinks consumed changed over time?  Yes       No  
If yes, please explain 
______________________________________________________________________________
____________ 
Cigarette/T
obacco
 U
se
 
 1. D
o
 you cu
rrently sm
oke
 o
r
 u
se
 tobacco
 produ
cts?
 
 Y
es
 
 
 
 
 
 
 N
o
  
 
 2. W
hat
 type
 of
 tobacco
 product
 do you gen
erally
 u
se?
 
 Cigarette
 
 
 
 
 
 Cigar
 
 
 
 
 
 
 Chew
ing tobacco
       
 Pipe
 
 
 
 
 
 O
ther
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 3. F
o
r
 how
 lo
ng hav
e
 yo
u
 been
 sm
oking or
 u
sing tobacco
 produ
cts?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
H
as
 this
 been
 co
ntin
u
o
u
s
 u
se?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
If
 n
o
, please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 4. Please
 estim
ate
 the
 n
u
m
ber
 of
 cigarettes/cigars/chew
ing tobacco/pipes
 y
o
u
 u
se
 daily________ w
eekly________ m
o
nthly_________
 
 5. H
as
 the
 n
u
m
ber
 of
 cig
arettes/cigars/chew
ing tobacco/pipes
 you use
 changed over
 the
 co
u
rse
 of
 tim
e?
 
 
 Y
es
 
 
 
 
 
 
 N
o
  
 
If
 yes
,
 please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 6. H
as
 the
 type
 of
 tobacco
 product
 u
sed ch
anged o
v
er
 tim
e?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 7. If
 you do not
 cu
rrently sm
oke
 o
r
 u
se
 tobacco
 products
,
 hav
e
 you ev
er?
 
 Y
es
 
 
 
 
 
 
 N
o
  
 
 8. W
hat
 type
 of
 tobacco
 product
 did you gen
erally use?
 Cigarette
 
 
 
 
 
 Cigar
 
 
 
 
 
 
 Chew
ing tobacco
      
 
 Pipe
 
 
 
 
 
 O
ther
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 9. F
o
r
 how
 lo
ng had you sm
oked or
 u
sed tobacco
 products?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
W
as
 this
 co
ntin
u
o
u
s
 u
se?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
If
 n
o
, please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 10. Please
 estim
ate
 the
 n
u
m
ber
 of
 cigarettes/cigars/chew
ing tobacco/pipes
 you used daily _______ w
eekly _______ m
o
nthly _______
 
 
 
 11. D
id the
 n
u
m
ber
 o
r
 type
 of
 cigarettes/cigars/ch
ew
ing tobacco/pipes
 you u
sed change
 o
v
er
 the
 co
u
rse
 of
 tim
e?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
 
If
 yes
,
 please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 12. If
 you do not
 cu
rrently sm
oke
 o
r
 u
se
 tobacco
 p
roducts
 but
 did in
 the
 past
,
 how
 lo
ng ago did you stop?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
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E
x
ercise/Physical
 A
ctivity 
  1. D
o
 you get
 regular
 (at
 least
 o
n
ce/w
eekly)
 ex
ercise?
 
 Y
es
 
 
 
 
 
 
 
 N
o
  
 
If
 yes
,
 please
 list:
 
 
a
.
 E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek
 
_
_
_
_
_
_
_
_
_
_
_
 duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
 
b. E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek ___________ duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
c
.
 E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek
 
_
_
_
_
_
_
_
_
_
_
_
 duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
d. E
x
ercise/physical
 activity _____________
_
_
_
_
_
_
_
_
 frequen
cy per
 w
eek ___________ duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
 2. H
as
 the
 am
o
u
nt
 o
r
 typ
e
 of
 ex
ercise
 that
 you engage
 in
 chang
ed over
 tim
e?
 
If
 yes
,
 please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 3. If
 you do not
 cu
rrently get
 regular
 ex
ercise
,
 hav
e
 you ev
er?
 
 Y
es
 
 
 
 
 
 
 N
o
  
 
If
 yes
,
 please
 list:
 
a
.
 E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek
 
_
_
_
_
_
_
_
_
_
_
_
 duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
 
b. E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek ___________ duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
c
.
 E
x
ercise/physical
 activity _____________________ freq
u
en
cy per
 w
eek
 
_
_
_
_
_
_
_
_
_
_
_
 duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
d. E
x
ercise/physical
 activity _____________________ frequen
cy per
 w
eek ___________ duratio
n
 per
 o
ccasio
n
 _
_
_
_
_
_
_
_
_
_
_
 
 4. If
 you do not
 cu
rrently get
 regular
 ex
ercise
 but
 did in
 the
 past
,
 how
 lo
ng
 has
 it
 been
 sin
ce
 you stopped?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 5. If
 you do not
 cu
rrently get
 regular
 ex
ercise
 but
 did in
 the
 past
,
 w
hat
 w
as
 the
 reaso
n(s)
 fo
r
 stopping?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 6. Please
 estim
ate
 your
 cu
rrent
 body type:
 
 O
v
erw
eight
 
 
 
 
 
 
 U
nderw
eight
 
 
 
 
 
 
 N
o
rm
al
-w
eighted 
 
 
 
 
 
7. If
 you are
 o
v
er
 o
r
 u
nderw
eight
,
 please
 estim
ate
 by how
 m
any pounds:
 
L
ess
 than
 10             10 to
 less
 than
 20        20 to
 less
 than
 30        30 to
 less
 than
 40         40 to
 less
 than
 50   
 
 
 
 
 
 M
o
re
 than
 50 
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G
en
eral
 H
ealth
 
 1. D
o
 you cu
rrently hav
e
 an
 infectio
n
 (e
.g., pneu
m
o
nia
,
 gingivitis
,
 bro
n
chitis)?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 w
h
at
 kind of
 infectio
n
 do you hav
e?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 fo
r
 how
 lo
ng?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 2. If
 you do not
 cu
rrently hav
e
 an
 infectio
n
, hav
e
 you ev
er?
 
 Y
es
 
 
 
 
 
 
 
 
 N
o
 
 
If
 yes
,
 w
h
at
 type
 of
 infectio
n
 did you hav
e?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 fo
r
 how
 lo
ng?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 3. If
 you do not
 cu
rrently hav
e
 an
 infectio
n
 but
 had one
 in
 th
e
 past
,
 how
 lo
ng ago w
as
 the
 infectio
n?
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 4. If
 you cu
rrently hav
e
 an
 infectio
n
 o
r
 had on
e
 in
 the
 past
,
 did you undergo
 any type
 treatm
ent?
 
 Y
es
 
 
 
 
 
 
 
 N
o
      
If
 yes
,
 please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 5. If
 you receiv
ed treatm
ent
 fo
r
 a
 cu
rrent
 o
r
 past
 infectio
n
, did you follo
w
 the
 prescribed advice?
 
 Y
es
 
 
 
 
 
 
 
 N
o
 
 
If
 n
o
, please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 6. If
 you receiv
ed treatm
ent
 fo
r
 a
 cu
rrent
 o
r
 past
 infectio
n
, did the
 treatm
ent
 help?
 
 Y
es
 
 
 
 
 
 
 N
o
 
 
Please
 explain
:
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
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 an
 inflam
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ry co
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n
 (e
.g., rheu
m
atoid arthritis
,
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,
 gout)?
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,
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n
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 8. If
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10. If
 you cu
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 had one
 in
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 past
,
 did you undergo any type
 treatm
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,
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 11. If
 you receiv
ed treatm
ent
 fo
r
 a
 cu
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 o
r
 p
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 inflam
m
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ry co
nditio
n
, did you follo
w
 the
 prescribed advice?
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o
, please
 explain
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 12. If
 you receiv
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r
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r
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n
, did the
 treatm
ent
 help?
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F
o
r
 F
em
ales
 O
nly:
 
 1. A
re
 you cu
rrently on birth co
ntrol
,
 estrogen
, o
r
 other
 horm
o
n
e
 replacem
ent
 therapy (H
R
T)?
 
 
 Y
es
 
 
 
 
 
 
 
 N
o
   
If
 yes
,
 please
 list:
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 2. If
 you are
 cu
rrently on
 birth co
ntrol
,
 estrogen
, o
r
 an
other
 H
R
T
,
 fo
r
 how
 lo
ng hav
e
 you been
 m
edicated?
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 been
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u
o
u
s
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o
, please
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 3. If
 you are
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 been
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 the
 past?
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,
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 Elevated blood levels of C-reactive protein (CRP) and homocysteine (Hcy) have 
received a great deal of attention as biomarkers for the development of cardiovascular 
disease. Their utility in predicting cognitive function has also been assessed, though the 
findings are equivocal. The current study examined the relationship between elevated 
blood levels of CRP and Hcy and their effect on cognition across several cognitive 
domains. As baseline blood levels of CRP and Hcy and cognition are in part regulated 
by genetic factors, the impact of T carrier status for variants in the CRP -286 C>T>A 
and the MTHFR 677C>T alleles was also examined. In an exceptionally healthy aging 
population free of overt signs of cardiovascular disease, normal range elevations in 
blood levels of CRP or Hcy, either alone or in combination, were not associated with 
cognitive impairments in any domain. Moreover, T carriage for either SNP was 
unrelated CRP or Hcy blood levels, and was only related to cognition in a task and 
subpopulation specific manner. Namely, T carriers of the CRP gene had reduced 
processing speed, and among men, reduced ‘g’ performance. Whereas for the MTHFR 
gene, T carriage was associated with fewer prose items recalled among hypertensives.
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